[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Hospira Inc.\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":160},{"warningLetters":4,"total":159},[5,33,56,76,97,117,135],{"id":6,"raw":7,"subject":12,"body_html":15,"body_text":16,"firm_name":17,"letter_id":18,"created_at":19,"fei_number":20,"letter_url":21,"updated_at":22,"action_type":23,"case_status":24,"posted_date":25,"marcs_cms_no":26,"product_type":27,"closeout_date":28,"issuing_office":11,"recipient_name":29,"body_fetched_at":30,"delivery_method":31,"recipient_title":20,"reference_number":20,"action_taken_date":32,"medical_device_id":20,"response_letter_date":20},2676,[8,9,10,11,12,13,14,13],"\u003Ctime datetime=\"2022-05-10T13:20:00Z\">05\u002F10\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-04-11T04:00:00Z\">04\u002F11\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbrigham-and-womens-hospital-inc-623476-04112022\">Brigham and Women’s Hospital Inc.\u003C\u002Fa>","Office of Pharmaceutical Quality Operations Division I","CGMP\u002FPositron Emission Tomography (PET) Drugs\u002FAdulterated","","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbrigham-and-womens-hospital-inc-623476-05242023\">\u003Ctime datetime=\"2023-05-31T04:00:00Z\">05\u002F31\u002F2023\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Sunil Eppen, MD\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Interim President and Chief Medical Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Brigham and Women’s Hospital Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>15 Francis Street\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Boston\u003C\u002Fspan>, \u003Cspan>MA\u003C\u002Fspan> \u003Cspan>02115\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:seppen@partners.org\"> seppen@partners.org\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Pharmaceutical Quality Operations Division I\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nWL # 623476\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>April 11, 2022\u003C\u002Fp>\n\n\u003Cp>Dear Dr. Eppen:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Brigham and Women’s Hospital Inc., FEI 3012030543, located at 75 Francis Street, Boston, MA from August 5 to September 16, 2021.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for positron emission tomography (PET) drugs. See Title 21 Code of Federal Regulations (CFR), part 212 (21 CFR part 212).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your PET drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>We reviewed your October 12, 2021 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your facilities are not adequate to ensure the prevention of contamination of equipment or product by substances, personnel, or environmental conditions that could reasonably be expected to have an adverse effect on product quality. Procedures to ensure that all equipment is clean, suitable for its intended purposes, properly installed, maintained, and capable of repeatedly producing valid results, are not adequately followed. (21 CFR 212.30(a) and (b)).\u003C\u002Fstrong>\u003Cbr>\n\u003Cbr>\nYou manufacture PET drug products for parenteral administration in a facility that is not adequately designed or controlled for aseptic processing. In addition, you did not ensure that your equipment is suitable for aseptic operations.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Facility Suitability\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>You failed to provide adequate facilities for the prevention of contamination.\u003C\u002Fp>\n\n\u003Cp>From about July 1, 2020 through October 1, 2020, your facility experienced a series of water infiltrations in and around your Technical Corridor. The water infiltrations occurred in this uncontrolled and unclassified area, which is located behind, and above equipment used in the PET aseptic production operation, including your hot cells, biological safety cabinet, and laminar flow hood. During the inspection, investigators also observed an overhead water supply pipe actively leaking onto the floor within your raw material storage area. Furthermore, your environmental monitoring (EM) program revealed several fungal species in your facility’s ISO 5 classified environments, such as your hot cell used for the manufacturing of drug product [\u003Csup>18\u003C\u002Fsup>F]-Fludeoxyglucose for Injection. In your investigation, you attributed the fungal recoveries in the ISO 5 classified environment to the water infiltrations. Your investigation states that the water infiltrations were due to multiple failures associated with the mechanical suite above your manufacturing area and with the roof penetrations leading into the plenum spaces above your cleanroom areas. Notably, the EM data indicates that the water infiltration problem preceded the date of detection and manifested as a loss of environmental control in your aseptic production facility. The failure to appropriately design and maintain the facility led to a lack of control and subjected drug products to the risk of contamination.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Equipment\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>From June 29, 2020 to November 25, 2020, your EM program repeatedly recovered microorganisms, including several fungal organisms, from your facility’s ISO 5 areas. Air monitoring in critical areas should normally yield no microbiological contamination. Your EM program also recovered many of the same organisms in the adjacent ISO 7 areas. During this time, you manufactured drug products including \u003Cstrong>(b)(4)\u003C\u002Fstrong> batches of [\u003Csup>18\u003C\u002Fsup>F]-Fludeoxyglucose for Injection and \u003Cstrong>(b)(4)\u003C\u002Fstrong> sub-batches of [\u003Csup>13\u003C\u002Fsup>N]-Ammonia for Injection. You acknowledged in your response that you failed to apply the appropriate minimum contact time for a sporicidal disinfectant used within the ISO 5 area of your biological safety cabinets and hot cells. Additionally, we observed an operator insert their upper torso and head into your biological safety cabinet while performing the cleaning and disinfection process. Furthermore, you failed to ensure all operators completed their media fill qualifications within your established requalification periods, which is a repeat issue from your 2019 inspection. Finally, you failed to adequately follow your procedures to investigate each ISO 5 EM result exceeding action level to determine product impact, identify root causes, and to implement effective corrective actions and preventive actions (CAPA).\u003C\u002Fp>\n\n\u003Cp>In your response, you stated that your engineering department conducted responsive emergency remediations for each water infiltration, and that your facility was returned to a state of control in November 2020. However, you halted any further remediations in favor of a “comprehensive” repair project to be completed in February 2022. Your response also indicates that you will continue PET drug manufacturing while remediating your facility. You did not discuss your plans to proactively assess your facility and the Technical Corridor for its adequacy to manufacture PET drugs, including the prevention of contamination. Your response is inadequate because you did not include a sufficient plan for ensuring that your facility is robustly designed and maintained. Furthermore, you did not explain what additional steps you would take to prevent contamination while you continue manufacturing during remediations. Your response also failed to sufficiently address your ISO 5 decontamination program to improve its robustness such as assessing the potential for increasing disinfection frequency, ensuring more comprehensive application of disinfectants to all surfaces in critical environments and surrounding environments, and other steps that would ensure more effective disinfection.\u003C\u002Fp>\n\n\u003Cp>Your response also acknowledged the need to investigate each quality related event. As a correction, you revised your \u003Cem>Quality Management Systems\u003C\u002Fem> SOP to reinforce investigation and reporting of all quality related events as required by your \u003Cem>Environmental Control\u003C\u002Fem> SOP and your&nbsp;\u003Cem>Interpretation\u002FInvestigation of Positive Media Results\u003C\u002Fem> SOP. Your response is inadequate because you did not describe why you failed to follow your established procedures nor indicate how you intend to assure that your written procedures will be consistently followed in the future.\u003C\u002Fp>\n\n\u003Cp>PET drug products have short expiry periods. Consequently, PET drug products are released and administered before the results of batch specific sterility testing and EM are known. Your ongoing EM program is essential to detect and respond to potential product contamination hazards in your manufacturing environment in a timely manner. Loss of environmental control in an aseptic manufacturing facility can ultimately pose a serious hazard to patients.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Comprehensive risk assessment of all contamination hazards with respect to your aseptic processes, equipment, and facilities, including an independent assessment that includes, but is not limited to:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>o All human interactions within ISO 5 areas\u003Cbr>\no Equipment placement and ergonomics\u003Cbr>\no Air quality in ISO 5 areas and the surrounding areas\u003Cbr>\no Facility layout\u003Cbr>\no Personnel Flows and Material Flows (throughout all rooms used to conduct and support sterile operations)\u003Cbr>\no Facility management systems and environmental controls (e.g., temperature, humidity, air handling, interactions of areas of differing classifications)\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A detailed remediation plan with timelines to address the findings of the independent contamination hazards risk assessment. Describe specific tangible improvements to be made to aseptic processing operation design, control, and maintenance.\u003C\u002Fli>\n\t\u003Cli>Your plans and results evaluating whether an adequate state of control was maintained for PET drug production during your facility remediation activities.\u003C\u002Fli>\n\t\u003Cli>A list of all environmental monitoring results outside alert and action limits for ISO 5 and ISO 7 areas since November 2020.\u003C\u002Fli>\n\t\u003Cli>Your CAPA plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, timely upgrades to equipment and facilities, adherence to appropriate preventive maintenance schedules, effective execution of repairs, and improved systems for ongoing management review.\u003C\u002Fli>\n\t\u003Cli>Your procedures for conducting routine facility walkthroughs, at appropriate frequencies, to assess the state of repair of your facility in order to mitigate contamination hazards.\u003C\u002Fli>\n\t\u003Cli>Evaluation whether cleaning and disinfecting methods (e.g., agents, procedures, frequency) used in all classified areas are effective.\u003C\u002Fli>\n\t\u003Cli>Your facility qualifications, media fills, and most recent static and dynamic smoke studies performed for both the biological safety cabinet and laminar flow hood during and since completion of the facility remediation.\u003C\u002Fli>\n\t\u003Cli>Complete investigations into all batches with potential microbial contamination. The investigations should detail your findings regarding the root causes of the contamination.\u003C\u002Fli>\n\t\u003Cli>Appropriate microbiological raw material, in-process, and batch release specifications (i.e., sterility, endotoxin, total counts, appropriate identification of in-process bioburden flora) for each of your drug products.\u003C\u002Fli>\n\t\u003Cli>Your plan to ensure your staff will adhere to your established procedures.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to conduct adequate investigations and take appropriate corrective action when a failure of a production batch or any component of the batch failed to meet any of its specifications. (21 CFR 212.20(d)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You failed to conduct adequate investigations into multiple out-of-specification (OOS) endotoxin results, including implementing appropriate and effective CAPAs.\u003C\u002Fp>\n\n\u003Cp>For example, analysis of drug product [\u003Csup>13\u003C\u002Fsup>N]-Ammonia for Injection, batch 13NNH3210511-A revealed an OOS result for endotoxins, and the batch was released without an adequate investigation. An initial OOS test result was invalidated due to a system suitability failure. A second analysis, which met system suitability criteria, obtained an OOS result of 30.7 EU\u002FmL (exceeding your \u003Cstrong>(b)(4)\u003C\u002Fstrong> EU\u002FmL specification). You resampled from the final product vial and conducted another test, which met the specification. You repeated the analysis, which also yielded a passing result. You released the batch and subsequent sub-batches based on the passing results.\u003C\u002Fp>\n\n\u003Cp>You invalidated the OOS result without conducting an adequate investigation for potential sources of contamination, and concluded that “concerns with \u003Cstrong>(b)(4)\u003C\u002Fstrong> were confirmed using a new bottle of&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>”. Your investigation failed to include testing of the initial reagent bottle of \u003Cstrong>(b)(4)\u003C\u002Fstrong> to support your assumed cause of the OOS. Your investigation also did not clearly identify errors by the laboratory in the handling of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> as the cause of the OOS. Your investigation also identified neither corrective nor preventive actions. Despite a failure to clearly establish a laboratory cause, you did not extend your investigation into potential manufacturing causes. The investigation failed to evaluate the potential sources of endotoxin contamination from the upstream process including contamination from manufacturing equipment, raw materials, processing conditions, or the working environment.\u003C\u002Fp>\n\n\u003Cp>In your response, you revised your \u003Cem>Quality Management System SOP \u003C\u002Fem>to include concepts from FDA’s\u003Cem> Guidance for Industry, Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production\u003C\u002Fem> and standardized your reporting format. However, your response is inadequate because you did not provide a retrospective evaluation of OOS endotoxin testing results. It is also unclear whether you revised your Pyrogen Testing SOP to reflect revisions to your \u003Cem>Quality Management System\u003C\u002Fem> SOP, as your \u003Cem>Pyrogen Testing\u003C\u002Fem> SOP still allows the testing of OOS endotoxin results until \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>passing results are obtained without limiting the number of retests that can be conducted.\u003C\u002Fp>\n\n\u003Cp>For more information about pyrogen and endotoxin testing, see FDA’s \u003Cem>Guidance for Industry Pyrogen and Endotoxins Testing: Questions and Answers\u003C\u002Fem> \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F83477\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F83477\u002Fdownload\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A retrospective review of all invalidated OOS (including in-process and release\u002Fstability testing) results for PET drug products and a report summarizing the findings of the analysis, including the following for each OOS:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>o Determine whether the scientific justification and evidence related to the invalidated OOS result conclusively or inconclusively demonstrates causative laboratory error.\u003Cbr>\no For investigations that conclusively establish laboratory root cause, provide rationale and ensure that all other laboratory methods vulnerable to the same or similar root cause are identified for remediation.\u003Cbr>\no For all OOS results found by the retrospective review to have an inconclusive or no root cause identified in the laboratory, include a thorough review of production (e.g., batch manufacturing records, adequacy of the manufacturing steps, suitability of equipment\u002Ffacilities, variability of raw materials, process capability, deviation history, complaint history, batch failure history). Provide a summary of potential manufacturing root causes for each investigation, and any manufacturing operation improvements.\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive review and remediation plan for your OOS result investigation systems. The CAPA should include but not be limited to addressing the following:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>o Quality unit oversight of laboratory investigations\u003Cbr>\no Identification of adverse laboratory control trends\u003Cbr>\no Resolution of causes of laboratory variation\u003Cbr>\no Initiation of thorough investigations of potential manufacturing causes whenever a laboratory cause cannot be conclusively identified\u003Cbr>\no Adequately scoping of each investigation and its CAPA\u003Cbr>\no Revised OOS investigation procedures with these and other remediations\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Guidance on Positron Emission Tomography (PET) Drugs\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>See FDA’s guidance document, PET Drugs—Current Good Manufacturing Practice, to help you meet the CGMP requirements when manufacturing PET drugs, at&nbsp;\u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71013\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71013\u002Fdownload\u003C\u002Fa>. This guidance document also references FDA’s guidance document, \u003Cem>Sterile Drug Products Produced by Aseptic Processing—Current Good Manufacturing Practice\u003C\u002Fem> for additional concepts and expectations that may apply to PET drug manufacturing, at&nbsp;\u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71026\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71026\u002Fdownload\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified to evaluate your operations to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>If you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\n\n\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>If you believe that your products are not in violation of the FD&amp;C Act (or you have complied with FDA regulations), include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to ORAPHARM1_RESPONSES@fda.hhs.gov. Your written notification should refer to Warning Letter # 623476 and include FEI: 3012030543.\u003C\u002Fp>\n\n\u003Cp>If you have questions regarding the content of this letter, please contact CDR Liatte Closs, Compliance Officer, at liatte.closs@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Craig Swanson\u003Cbr>\nActing Program Division Director\u002FDistrict Director\u003Cbr>\nOffice of Pharmaceutical Quality Operations Division I\u003Cbr>\nNew Jersey District\u003C\u002Fp>\n\n\u003Cp>CC: Peter Holton, Director of Operations BICOR\u003Cbr>\nBrigham and Women’s Hospital Inc.\u003Cbr>\n75 Francis Street\u003Cbr>\nBoston, MA 02115\u003Cbr>\nEmail: pholton@partners.org\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nSunil Eppen, MD\n\nRecipient Title\n\nInterim President and Chief Medical Officer\n\nBrigham and Women’s Hospital Inc.\n\n15 Francis Street\n\nBoston, MA 02115\n\nUnited States\n\nseppen@partners.org\n\nIssuing Office:\n\nOffice of Pharmaceutical Quality Operations Division I\n\nUnited States\n\nWARNING LETTER\n\nWL # 623476\n\nApril 11, 2022\n\nDear Dr. Eppen:\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Brigham and Women’s Hospital Inc., FEI 3012030543, located at 75 Francis Street, Boston, MA from August 5 to September 16, 2021.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for positron emission tomography (PET) drugs. See Title 21 Code of Federal Regulations (CFR), part 212 (21 CFR part 212).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your PET drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nWe reviewed your October 12, 2021 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\n\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n\n1. Your facilities are not adequate to ensure the prevention of contamination of equipment or product by substances, personnel, or environmental conditions that could reasonably be expected to have an adverse effect on product quality. Procedures to ensure that all equipment is clean, suitable for its intended purposes, properly installed, maintained, and capable of repeatedly producing valid results, are not adequately followed. (21 CFR 212.30(a) and (b)).\n\nYou manufacture PET drug products for parenteral administration in a facility that is not adequately designed or controlled for aseptic processing. In addition, you did not ensure that your equipment is suitable for aseptic operations.\n\nFacility Suitability\n\nYou failed to provide adequate facilities for the prevention of contamination.\n\nFrom about July 1, 2020 through October 1, 2020, your facility experienced a series of water infiltrations in and around your Technical Corridor. The water infiltrations occurred in this uncontrolled and unclassified area, which is located behind, and above equipment used in the PET aseptic production operation, including your hot cells, biological safety cabinet, and laminar flow hood. During the inspection, investigators also observed an overhead water supply pipe actively leaking onto the floor within your raw material storage area. Furthermore, your environmental monitoring (EM) program revealed several fungal species in your facility’s ISO 5 classified environments, such as your hot cell used for the manufacturing of drug product [18F]-Fludeoxyglucose for Injection. In your investigation, you attributed the fungal recoveries in the ISO 5 classified environment to the water infiltrations. Your investigation states that the water infiltrations were due to multiple failures associated with the mechanical suite above your manufacturing area and with the roof penetrations leading into the plenum spaces above your cleanroom areas. Notably, the EM data indicates that the water infiltration problem preceded the date of detection and manifested as a loss of environmental control in your aseptic production facility. The failure to appropriately design and maintain the facility led to a lack of control and subjected drug products to the risk of contamination.\n\nEquipment\n\nFrom June 29, 2020 to November 25, 2020, your EM program repeatedly recovered microorganisms, including several fungal organisms, from your facility’s ISO 5 areas. Air monitoring in critical areas should normally yield no microbiological contamination. Your EM program also recovered many of the same organisms in the adjacent ISO 7 areas. During this time, you manufactured drug products including (b)(4) batches of [18F]-Fludeoxyglucose for Injection and (b)(4) sub-batches of [13N]-Ammonia for Injection. You acknowledged in your response that you failed to apply the appropriate minimum contact time for a sporicidal disinfectant used within the ISO 5 area of your biological safety cabinets and hot cells. Additionally, we observed an operator insert their upper torso and head into your biological safety cabinet while performing the cleaning and disinfection process. Furthermore, you failed to ensure all operators completed their media fill qualifications within your established requalification periods, which is a repeat issue from your 2019 inspection. Finally, you failed to adequately follow your procedures to investigate each ISO 5 EM result exceeding action level to determine product impact, identify root causes, and to implement effective corrective actions and preventive actions (CAPA).\n\nIn your response, you stated that your engineering department conducted responsive emergency remediations for each water infiltration, and that your facility was returned to a state of control in November 2020. However, you halted any further remediations in favor of a “comprehensive” repair project to be completed in February 2022. Your response also indicates that you will continue PET drug manufacturing while remediating your facility. You did not discuss your plans to proactively assess your facility and the Technical Corridor for its adequacy to manufacture PET drugs, including the prevention of contamination. Your response is inadequate because you did not include a sufficient plan for ensuring that your facility is robustly designed and maintained. Furthermore, you did not explain what additional steps you would take to prevent contamination while you continue manufacturing during remediations. Your response also failed to sufficiently address your ISO 5 decontamination program to improve its robustness such as assessing the potential for increasing disinfection frequency, ensuring more comprehensive application of disinfectants to all surfaces in critical environments and surrounding environments, and other steps that would ensure more effective disinfection.\n\nYour response also acknowledged the need to investigate each quality related event. As a correction, you revised your Quality Management Systems SOP to reinforce investigation and reporting of all quality related events as required by your Environmental Control SOP and your Interpretation\u002FInvestigation of Positive Media Results SOP. Your response is inadequate because you did not describe why you failed to follow your established procedures nor indicate how you intend to assure that your written procedures will be consistently followed in the future.\n\nPET drug products have short expiry periods. Consequently, PET drug products are released and administered before the results of batch specific sterility testing and EM are known. Your ongoing EM program is essential to detect and respond to potential product contamination hazards in your manufacturing environment in a timely manner. Loss of environmental control in an aseptic manufacturing facility can ultimately pose a serious hazard to patients.\n\nIn response to this letter, provide the following:\n\nComprehensive risk assessment of all contamination hazards with respect to your aseptic processes, equipment, and facilities, including an independent assessment that includes, but is not limited to:\n\no All human interactions within ISO 5 areas\n\no Equipment placement and ergonomics\n\no Air quality in ISO 5 areas and the surrounding areas\n\no Facility layout\n\no Personnel Flows and Material Flows (throughout all rooms used to conduct and support sterile operations)\n\no Facility management systems and environmental controls (e.g., temperature, humidity, air handling, interactions of areas of differing classifications)\n\nA detailed remediation plan with timelines to address the findings of the independent contamination hazards risk assessment. Describe specific tangible improvements to be made to aseptic processing operation design, control, and maintenance.\n\nYour plans and results evaluating whether an adequate state of control was maintained for PET drug production during your facility remediation activities.\n\nA list of all environmental monitoring results outside alert and action limits for ISO 5 and ISO 7 areas since November 2020.\n\nYour CAPA plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, timely upgrades to equipment and facilities, adherence to appropriate preventive maintenance schedules, effective execution of repairs, and improved systems for ongoing management review.\n\nYour procedures for conducting routine facility walkthroughs, at appropriate frequencies, to assess the state of repair of your facility in order to mitigate contamination hazards.\n\nEvaluation whether cleaning and disinfecting methods (e.g., agents, procedures, frequency) used in all classified areas are effective.\n\nYour facility qualifications, media fills, and most recent static and dynamic smoke studies performed for both the biological safety cabinet and laminar flow hood during and since completion of the facility remediation.\n\nComplete investigations into all batches with potential microbial contamination. The investigations should detail your findings regarding the root causes of the contamination.\n\nAppropriate microbiological raw material, in-process, and batch release specifications (i.e., sterility, endotoxin, total counts, appropriate identification of in-process bioburden flora) for each of your drug products.\n\nYour plan to ensure your staff will adhere to your established procedures.\n\n2. Your firm failed to conduct adequate investigations and take appropriate corrective action when a failure of a production batch or any component of the batch failed to meet any of its specifications. (21 CFR 212.20(d)).\n\nYou failed to conduct adequate investigations into multiple out-of-specification (OOS) endotoxin results, including implementing appropriate and effective CAPAs.\n\nFor example, analysis of drug product [13N]-Ammonia for Injection, batch 13NNH3210511-A revealed an OOS result for endotoxins, and the batch was released without an adequate investigation. An initial OOS test result was invalidated due to a system suitability failure. A second analysis, which met system suitability criteria, obtained an OOS result of 30.7 EU\u002FmL (exceeding your (b)(4) EU\u002FmL specification). You resampled from the final product vial and conducted another test, which met the specification. You repeated the analysis, which also yielded a passing result. You released the batch and subsequent sub-batches based on the passing results.\n\nYou invalidated the OOS result without conducting an adequate investigation for potential sources of contamination, and concluded that “concerns with (b)(4) were confirmed using a new bottle of (b)(4)”. Your investigation failed to include testing of the initial reagent bottle of (b)(4) to support your assumed cause of the OOS. Your investigation also did not clearly identify errors by the laboratory in the handling of the (b)(4) as the cause of the OOS. Your investigation also identified neither corrective nor preventive actions. Despite a failure to clearly establish a laboratory cause, you did not extend your investigation into potential manufacturing causes. The investigation failed to evaluate the potential sources of endotoxin contamination from the upstream process including contamination from manufacturing equipment, raw materials, processing conditions, or the working environment.\n\nIn your response, you revised your Quality Management System SOP to include concepts from FDA’s Guidance for Industry, Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production and standardized your reporting format. However, your response is inadequate because you did not provide a retrospective evaluation of OOS endotoxin testing results. It is also unclear whether you revised your Pyrogen Testing SOP to reflect revisions to your Quality Management System SOP, as your Pyrogen Testing SOP still allows the testing of OOS endotoxin results until (b)(4) passing results are obtained without limiting the number of retests that can be conducted.\n\nFor more information about pyrogen and endotoxin testing, see FDA’s Guidance for Industry Pyrogen and Endotoxins Testing: Questions and Answers https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F83477\u002Fdownload.\n\nIn response to this letter, provide the following:\n\nA retrospective review of all invalidated OOS (including in-process and release\u002Fstability testing) results for PET drug products and a report summarizing the findings of the analysis, including the following for each OOS:\n\no Determine whether the scientific justification and evidence related to the invalidated OOS result conclusively or inconclusively demonstrates causative laboratory error.\n\no For investigations that conclusively establish laboratory root cause, provide rationale and ensure that all other laboratory methods vulnerable to the same or similar root cause are identified for remediation.\n\no For all OOS results found by the retrospective review to have an inconclusive or no root cause identified in the laboratory, include a thorough review of production (e.g., batch manufacturing records, adequacy of the manufacturing steps, suitability of equipment\u002Ffacilities, variability of raw materials, process capability, deviation history, complaint history, batch failure history). Provide a summary of potential manufacturing root causes for each investigation, and any manufacturing operation improvements.\n\nA comprehensive review and remediation plan for your OOS result investigation systems. The CAPA should include but not be limited to addressing the following:\n\no Quality unit oversight of laboratory investigations\n\no Identification of adverse laboratory control trends\n\no Resolution of causes of laboratory variation\n\no Initiation of thorough investigations of potential manufacturing causes whenever a laboratory cause cannot be conclusively identified\n\no Adequately scoping of each investigation and its CAPA\n\no Revised OOS investigation procedures with these and other remediations\n\nGuidance on Positron Emission Tomography (PET) Drugs\n\nSee FDA’s guidance document, PET Drugs—Current Good Manufacturing Practice, to help you meet the CGMP requirements when manufacturing PET drugs, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71013\u002Fdownload. This guidance document also references FDA’s guidance document, Sterile Drug Products Produced by Aseptic Processing—Current Good Manufacturing Practice for additional concepts and expectations that may apply to PET drug manufacturing, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71026\u002Fdownload.\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified to evaluate your operations to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nIf you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\n\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\n\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nIf you believe that your products are not in violation of the FD&C Act (or you have complied with FDA regulations), include your reasoning and any supporting information for our consideration.\n\nSend your electronic reply to ORAPHARM1_RESPONSES@fda.hhs.gov. Your written notification should refer to Warning Letter # 623476 and include FEI: 3012030543.\n\nIf you have questions regarding the content of this letter, please contact CDR Liatte Closs, Compliance Officer, at liatte.closs@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nCraig Swanson\n\nActing Program Division Director\u002FDistrict Director\n\nOffice of Pharmaceutical Quality Operations Division I\n\nNew Jersey District\n\nCC: Peter Holton, Director of Operations BICOR\n\nBrigham and Women’s Hospital Inc.\n\n75 Francis Street\n\nBoston, MA 02115\n\nEmail: pholton@partners.org","Brigham and Women’s Hospital Inc.","brigham-and-womens-hospital-inc-623476-04112022","2026-08-18T06:42:29.262718+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbrigham-and-womens-hospital-inc-623476-04112022","2026-10-26T08:08:09.039632+00:00","Warning Letter","Closed Out","2022-05-10","623476","Drugs","2023-05-31","Sunil Eppen, MD","2026-08-20T01:55:00.042+00:00","VIA Electronic Mail","2022-04-11",{"id":34,"raw":35,"subject":40,"body_html":41,"body_text":42,"firm_name":43,"letter_id":44,"created_at":45,"fei_number":20,"letter_url":46,"updated_at":47,"action_type":23,"case_status":48,"posted_date":49,"marcs_cms_no":50,"product_type":27,"closeout_date":20,"issuing_office":39,"recipient_name":51,"body_fetched_at":52,"delivery_method":53,"recipient_title":20,"reference_number":54,"action_taken_date":55,"medical_device_id":20,"response_letter_date":20},1181,[36,37,38,39,40,13,13,13],"\u003Ctime datetime=\"2024-11-05T14:20:00Z\">11\u002F05\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-10-29T04:00:00Z\">10\u002F29\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Farmstrong-county-memorial-hospital-692080-10292024\">Armstrong County Memorial Hospital\u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","Institutional Review Board (IRB)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>24-HFD-45-10-01\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Nichole Geraci, MBA\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President &amp; Chief Executive Officer \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Armstrong County Memorial Hospital\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1 Nolte Drive\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Kittanning\u003C\u002Fspan>, \u003Cspan>PA\u003C\u002Fspan> \u003Cspan>16201\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA Ref. No.: 24-HFD-45-10-01\u003C\u002Fp>\n\n\u003Cp>Dear Ms. Geraci:\u003C\u002Fp>\n\n\u003Cp>This Warning Letter informs you of objectionable conditions observed during the U.S. Food and Drug Administration (FDA) inspection conducted between November 2, 2023, and November 8, 2023, of the Armstrong County Memorial Hospital (ACMH) Institutional Review Board (IRB). Investigator Cynthia L. Rakestraw, representing FDA, conducted the inspection to determine whether the IRB’s procedures for the protection of human subjects complied with FDA regulations contained in Title 21 of the Code of Federal Regulations (21 CFR), parts 50 and 56. These regulations apply to clinical investigations of products regulated by FDA.\u003C\u002Fp>\n\n\u003Cp>This inspection is a part of FDA’s Bioresearch Monitoring Program, which includes inspections designed to evaluate the conduct of research and to help ensure that the rights, safety, and welfare of the human subjects of those studies have been protected.\u003C\u002Fp>\n\n\u003Cp>At the conclusion of the inspection, Investigator Rakestraw presented and discussed with you the Form FDA 483, Inspectional Observations. We acknowledge receipt of the ACMH IRB’s November 13 to 15, 2023, written responses to the Form FDA 483.\u003C\u002Fp>\n\n\u003Cp>From our review of the FDA Establishment Inspection Report, the documents submitted with that report, and the ACMH IRB’s November 13 to 15, 2023, written responses, it appears that the ACMH IRB did not adhere to applicable statutory requirements in the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) and FDA regulations governing the protection of human subjects.\u003C\u002Fp>\n\n\u003Cp>We wish to emphasize the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. The IRB failed to prepare, maintain, and follow written procedures governing the functions and operations of the IRB [21 CFR 56.108(a) and (b); 21 CFR 56.115(a)(6)].\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>To fulfill the requirements of the IRB regulations, each IRB must prepare, maintain, and follow written procedures describing the IRB’s functions and operations that are specified in the regulations [21 CFR 56.108(a) and (b); 56.115(a)(6)]. The ACMH IRB failed to adhere to these requirements. Specifically, the ACMH IRB failed to prepare, maintain, and follow such written procedures as follows:\u003C\u002Fp>\n\n\u003Cp>a. The ACMH IRB failed to follow, and to prepare and maintain adequate documentation of, written procedures for reporting its findings and actions regarding initial and continuing review to the investigator and the institution [21 CFR 56.108(a)(1); 21 CFR 56.115(a)(6)].\u003C\u002Fp>\n\n\u003Cp>b. The ACMH IRB failed to follow, and to prepare and maintain adequate documentation of, written procedures for determining which projects require review more often than annually, and which projects need verification from sources other than the investigator that no material changes have occurred since the previous IRB review [21 CFR 56.108(a)(2); 21 CFR 56.115(a)(6)].\u003C\u002Fp>\n\n\u003Cp>c. The ACMH IRB failed to follow, and to prepare and maintain adequate documentation of, written procedures for ensuring that changes in approved research, during the period for which IRB approval has already been given, may not be initiated without IRB review and approval, except where necessary to eliminate apparent immediate hazards to the human subjects [21 CFR 56.108(a)(4); 21 CFR 56.115(a)(6)].\u003C\u002Fp>\n\n\u003Cp>d. The ACMH IRB failed to follow, and to prepare and maintain adequate documentation of, written procedures for ensuring prompt reporting to the IRB, appropriate institutional officials, and the FDA of: (1) any unanticipated problems involving risks to human subjects or others; (2) any instance of serious or continuing noncompliance with these regulations or the requirements or determinations of the IRB; or (3) any suspension or termination of IRB approval [21 CFR 56.108(b); 21 CFR 56.115(a)(6)].\u003C\u002Fp>\n\n\u003Cp>We acknowledge that Item 1b. discussed above was not included on the Form FDA 483 you received, and that your written response therefore does not address this violation.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. The IRB failed to prepare and maintain adequate documentation of IRB activities, including minutes of IRB meetings [21 CFR 56.115(a)(2)].\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The ACMH IRB is required to prepare and maintain adequate documentation of IRB activities, including minutes of IRB meetings, which must be in sufficient detail to show attendance at the meetings; actions taken by the ACMH IRB; the votes on these actions, including the number of members voting for, against, and abstaining; the basis for requiring changes in or for disapproving research; and a written summary of the discussion of controverted issues and their resolution. The ACMH IRB failed to adhere to this requirement. Specifically:\u003C\u002Fp>\n\n\u003Cp>a. On May 18, 2021, at a convened meeting, the ACMH IRB reviewed and discussed continuing review for five FDA-regulated studies; however, the meeting minutes do not document the members who attended this meeting.\u003C\u002Fp>\n\n\u003Cp>b. On September 15, 2020, at a convened meeting, the ACMH IRB reviewed and discussed continuing review of an FDA-regulated humanitarian-use device study; however, the meeting minutes do not document the vote on actions taken by the ACMH IRB, including the number of members voting for, against, and abstaining.\u003C\u002Fp>\n\n\u003Cp>In the ACMH IRB’s November 13 to 15, 2023, written responses, the ACMH IRB stated its intent to close the IRB at ACMH and to transfer all responsibility to the IRB at Allegheny General Hospital.\u003C\u002Fp>\n\n\u003Cp>While we acknowledge that the ACMH IRB has stated its intent to close the IRB at ACMH and to transfer all responsibility to the IRB of another institution, your response is inadequate because you did not provide sufficient details about the IRB’s process for transferring IRB review and approval responsibilities for currently approved research studies to another registered IRB. Your response also did not provide sufficient details about the IRB’s plan for the review of research until the ACMH IRB transfers its\u003C\u002Fp>\n\n\u003Cp>responsibilities to another registered IRB, including how the ACMH IRB would address its failure: (1) to prepare, maintain, and follow written procedures describing the IRB’s functions and operations; and (2) to prepare and maintain adequate documentation of IRB meeting minutes. Without this information, we are unable to determine whether the IRB’s corrective action plan is adequate to prevent similar violations in the future.\u003C\u002Fp>\n\n\u003Cp>Please provide a projected timeline for the transfer of the ACMH IRB’s responsibilities to another registered IRB; any process regarding such a transfer; and any written procedures (or any revised written procedures in development) for the review of research until the ACMH IRB transfers its responsibilities to another registered IRB, including (1) procedures for the IRB’s functions and operations, as described in FDA regulations, and (2) procedures for the preparation and maintenance of adequate documentation of IRB meeting minutes.\u003C\u002Fp>\n\n\u003Cp>Failure to prepare and maintain adequate documentation of IRB activities, including written procedures and IRB meeting minutes, raises concerns about the adequacy of the IRB’s review process. Furthermore, inadequate documentation of meeting minutes raises concerns about whether the IRB members maintained a quorum for the duration of the ACMH IRB meetings.\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive list of deficiencies related to the ACMH IRB’s procedures or to the ACMH IRB’s review and approval of protocols. It is your responsibility to ensure adherence to each requirement of the law and relevant FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you with an opportunity to address the deficiencies described above. Within 15 business days of your receipt of this letter, you should notify this office in writing of the actions that the ACMH IRB has taken or plans to take to address any violations, and to prevent the recurrence of similar violations in the future. Failure to address this matter adequately may lead to regulatory action. If you believe that the ACMH IRB has complied with the FD&amp;C Act and FDA regulations, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>We recommend that you visit the following FDA Web page for information on human subject protections that may assist you in your efforts to come into compliance with FDA regulations: http:\u002F\u002Fwww.fda.gov\u002FScienceResearch\u002FSpecialTopics\u002FRunningClinicalTrials\u002Fdefault.htm.\u003C\u002Fp>\n\n\u003Cp>If the IRB has any questions, you may email FDA at CDER-OSI-Communications@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>The IRB’s written response and any pertinent documentation should be addressed to:\u003C\u002Fp>\n\n\u003Cp>Brittany L. Garr-Colón, MPH\u003Cbr>\nBranch Chief\u003Cbr>\nCompliance Enforcement Branch\u003Cbr>\nDivision of Enforcement and Postmarketing Safety\u003Cbr>\nOffice of Scientific Investigations\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nU.S. Food and Drug Administration\u003Cbr>\nBuilding 51, Room 5352\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n{See appended electronic signature page}\u003Cbr>\nDavid C. Burrow, Pharm.D., J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Scientific Investigations\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nU.S. Food and Drug Administration\u003Cbr>\n\u003Cbr>\n--------------------------------------------------------------------------------------------\u003Cbr>\nThis is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.\u003Cbr>\n--------------------------------------------------------------------------------------------\u003Cbr>\n\u002Fs\u002F\u003Cbr>\n------------------------------------------------------------\u003Cbr>\nDAVID C BURROW\u003Cbr>\n10\u002F29\u002F2024 07:12:47 AM\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nReference #:\n\n24-HFD-45-10-01\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nNichole Geraci, MBA\n\nRecipient Title\n\nPresident & Chief Executive Officer\n\nArmstrong County Memorial Hospital\n\n1 Nolte Drive\n\nKittanning, PA 16201\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\n\nFDA Ref. No.: 24-HFD-45-10-01\n\nDear Ms. Geraci:\n\nThis Warning Letter informs you of objectionable conditions observed during the U.S. Food and Drug Administration (FDA) inspection conducted between November 2, 2023, and November 8, 2023, of the Armstrong County Memorial Hospital (ACMH) Institutional Review Board (IRB). Investigator Cynthia L. Rakestraw, representing FDA, conducted the inspection to determine whether the IRB’s procedures for the protection of human subjects complied with FDA regulations contained in Title 21 of the Code of Federal Regulations (21 CFR), parts 50 and 56. These regulations apply to clinical investigations of products regulated by FDA.\n\nThis inspection is a part of FDA’s Bioresearch Monitoring Program, which includes inspections designed to evaluate the conduct of research and to help ensure that the rights, safety, and welfare of the human subjects of those studies have been protected.\n\nAt the conclusion of the inspection, Investigator Rakestraw presented and discussed with you the Form FDA 483, Inspectional Observations. We acknowledge receipt of the ACMH IRB’s November 13 to 15, 2023, written responses to the Form FDA 483.\n\nFrom our review of the FDA Establishment Inspection Report, the documents submitted with that report, and the ACMH IRB’s November 13 to 15, 2023, written responses, it appears that the ACMH IRB did not adhere to applicable statutory requirements in the Federal Food, Drug, and Cosmetic Act (FD&C Act) and FDA regulations governing the protection of human subjects.\n\nWe wish to emphasize the following:\n\n1. The IRB failed to prepare, maintain, and follow written procedures governing the functions and operations of the IRB [21 CFR 56.108(a) and (b); 21 CFR 56.115(a)(6)].\n\nTo fulfill the requirements of the IRB regulations, each IRB must prepare, maintain, and follow written procedures describing the IRB’s functions and operations that are specified in the regulations [21 CFR 56.108(a) and (b); 56.115(a)(6)]. The ACMH IRB failed to adhere to these requirements. Specifically, the ACMH IRB failed to prepare, maintain, and follow such written procedures as follows:\n\na. The ACMH IRB failed to follow, and to prepare and maintain adequate documentation of, written procedures for reporting its findings and actions regarding initial and continuing review to the investigator and the institution [21 CFR 56.108(a)(1); 21 CFR 56.115(a)(6)].\n\nb. The ACMH IRB failed to follow, and to prepare and maintain adequate documentation of, written procedures for determining which projects require review more often than annually, and which projects need verification from sources other than the investigator that no material changes have occurred since the previous IRB review [21 CFR 56.108(a)(2); 21 CFR 56.115(a)(6)].\n\nc. The ACMH IRB failed to follow, and to prepare and maintain adequate documentation of, written procedures for ensuring that changes in approved research, during the period for which IRB approval has already been given, may not be initiated without IRB review and approval, except where necessary to eliminate apparent immediate hazards to the human subjects [21 CFR 56.108(a)(4); 21 CFR 56.115(a)(6)].\n\nd. The ACMH IRB failed to follow, and to prepare and maintain adequate documentation of, written procedures for ensuring prompt reporting to the IRB, appropriate institutional officials, and the FDA of: (1) any unanticipated problems involving risks to human subjects or others; (2) any instance of serious or continuing noncompliance with these regulations or the requirements or determinations of the IRB; or (3) any suspension or termination of IRB approval [21 CFR 56.108(b); 21 CFR 56.115(a)(6)].\n\nWe acknowledge that Item 1b. discussed above was not included on the Form FDA 483 you received, and that your written response therefore does not address this violation.\n\n2. The IRB failed to prepare and maintain adequate documentation of IRB activities, including minutes of IRB meetings [21 CFR 56.115(a)(2)].\n\nThe ACMH IRB is required to prepare and maintain adequate documentation of IRB activities, including minutes of IRB meetings, which must be in sufficient detail to show attendance at the meetings; actions taken by the ACMH IRB; the votes on these actions, including the number of members voting for, against, and abstaining; the basis for requiring changes in or for disapproving research; and a written summary of the discussion of controverted issues and their resolution. The ACMH IRB failed to adhere to this requirement. Specifically:\n\na. On May 18, 2021, at a convened meeting, the ACMH IRB reviewed and discussed continuing review for five FDA-regulated studies; however, the meeting minutes do not document the members who attended this meeting.\n\nb. On September 15, 2020, at a convened meeting, the ACMH IRB reviewed and discussed continuing review of an FDA-regulated humanitarian-use device study; however, the meeting minutes do not document the vote on actions taken by the ACMH IRB, including the number of members voting for, against, and abstaining.\n\nIn the ACMH IRB’s November 13 to 15, 2023, written responses, the ACMH IRB stated its intent to close the IRB at ACMH and to transfer all responsibility to the IRB at Allegheny General Hospital.\n\nWhile we acknowledge that the ACMH IRB has stated its intent to close the IRB at ACMH and to transfer all responsibility to the IRB of another institution, your response is inadequate because you did not provide sufficient details about the IRB’s process for transferring IRB review and approval responsibilities for currently approved research studies to another registered IRB. Your response also did not provide sufficient details about the IRB’s plan for the review of research until the ACMH IRB transfers its\n\nresponsibilities to another registered IRB, including how the ACMH IRB would address its failure: (1) to prepare, maintain, and follow written procedures describing the IRB’s functions and operations; and (2) to prepare and maintain adequate documentation of IRB meeting minutes. Without this information, we are unable to determine whether the IRB’s corrective action plan is adequate to prevent similar violations in the future.\n\nPlease provide a projected timeline for the transfer of the ACMH IRB’s responsibilities to another registered IRB; any process regarding such a transfer; and any written procedures (or any revised written procedures in development) for the review of research until the ACMH IRB transfers its responsibilities to another registered IRB, including (1) procedures for the IRB’s functions and operations, as described in FDA regulations, and (2) procedures for the preparation and maintenance of adequate documentation of IRB meeting minutes.\n\nFailure to prepare and maintain adequate documentation of IRB activities, including written procedures and IRB meeting minutes, raises concerns about the adequacy of the IRB’s review process. Furthermore, inadequate documentation of meeting minutes raises concerns about whether the IRB members maintained a quorum for the duration of the ACMH IRB meetings.\n\nThis letter is not intended to be an all-inclusive list of deficiencies related to the ACMH IRB’s procedures or to the ACMH IRB’s review and approval of protocols. It is your responsibility to ensure adherence to each requirement of the law and relevant FDA regulations.\n\nThis letter notifies you of our findings and provides you with an opportunity to address the deficiencies described above. Within 15 business days of your receipt of this letter, you should notify this office in writing of the actions that the ACMH IRB has taken or plans to take to address any violations, and to prevent the recurrence of similar violations in the future. Failure to address this matter adequately may lead to regulatory action. If you believe that the ACMH IRB has complied with the FD&C Act and FDA regulations, include your reasoning and any supporting information for our consideration.\n\nWe recommend that you visit the following FDA Web page for information on human subject protections that may assist you in your efforts to come into compliance with FDA regulations: http:\u002F\u002Fwww.fda.gov\u002FScienceResearch\u002FSpecialTopics\u002FRunningClinicalTrials\u002Fdefault.htm.\n\nIf the IRB has any questions, you may email FDA at CDER-OSI-Communications@fda.hhs.gov.\n\nThe IRB’s written response and any pertinent documentation should be addressed to:\n\nBrittany L. Garr-Colón, MPH\n\nBranch Chief\n\nCompliance Enforcement Branch\n\nDivision of Enforcement and Postmarketing Safety\n\nOffice of Scientific Investigations\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nU.S. Food and Drug Administration\n\nBuilding 51, Room 5352\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993\n\nSincerely,\n\n{See appended electronic signature page}\n\nDavid C. Burrow, Pharm.D., J.D.\n\nDirector\n\nOffice of Scientific Investigations\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nU.S. Food and Drug Administration\n\n--------------------------------------------------------------------------------------------\n\nThis is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.\n\n--------------------------------------------------------------------------------------------\n\n\u002Fs\u002F\n\n------------------------------------------------------------\n\nDAVID C BURROW\n\n10\u002F29\u002F2024 07:12:47 AM","Armstrong County Memorial Hospital","armstrong-county-memorial-hospital-692080-10292024","2026-08-18T06:42:28.856152+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Farmstrong-county-memorial-hospital-692080-10292024","2026-10-26T08:07:57.5242+00:00","Issued","2024-11-05","692080","Nichole Geraci, MBA","2026-08-19T19:15:03.165+00:00","VIA UPS and Electronic Mail","24-HFD-45-10-01","2024-10-29",{"id":57,"raw":58,"subject":62,"body_html":63,"body_text":64,"firm_name":65,"letter_id":66,"created_at":67,"fei_number":20,"letter_url":68,"updated_at":69,"action_type":23,"case_status":48,"posted_date":70,"marcs_cms_no":71,"product_type":27,"closeout_date":20,"issuing_office":39,"recipient_name":20,"body_fetched_at":72,"delivery_method":73,"recipient_title":20,"reference_number":74,"action_taken_date":75,"medical_device_id":20,"response_letter_date":20},376,[59,60,61,39,62,13,13,13],"\u003Ctime datetime=\"2026-01-13T05:00:00Z\">01\u002F13\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-12-22T05:00:00Z\">12\u002F22\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fpurushothaman-damodara-kumaran-md-senthil-specialty-hospital-721325-12222025\">Purushothaman Damodara Kumaran, M.D. \u002F Senthil Specialty Hospital\u003C\u002Fa>","In Vivo Bioavailability-Bioequivalence Studies – Clinical","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE AND VIA E-MAIL\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>25-HFD-45-12-03\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>Purushothaman Damodara Kumaran, M.D. \u002F Senthil Specialty Hospital\u003C\u002Fdd>\n\n                      \u003Cdd>Senthil Specialty Hospital\u003C\u002Fdd>\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Number 10 and 12, Thillai Maistry Street\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Pondicherry\u003C\u002Fspan> \u003Cspan>605001\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Puducherry\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>India\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA Ref. No.: 25-HFD-45-12-03\u003C\u002Fp>\u003Cp>Dear Dr. Damodara Kumaran:\u003C\u002Fp>\u003Cp>This Warning Letter informs you of objectionable conditions observed during the U.S. Food and Drug Administration (FDA) inspection conducted at Senthil Specialty Hospital in Pondicherry, Puducherry, India, between January 20 and 24, 2025. The investigator representing FDA reviewed your conduct of a clinical in vivo bioequivalence study (Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong>, “\u003Cstrong>(b)(4)\u003C\u002Fstrong>”) of the investigational drug \u003Cstrong>(b)(4)\u003C\u002Fstrong>, performed for \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>This inspection was conducted as a part of FDA’s Bioresearch Monitoring Program, which includes inspections designed to evaluate the conduct of research and to help ensure that the rights, safety, and welfare of human subjects have been protected.\u003C\u002Fp>\u003Cp>At the conclusion of the inspection, the FDA investigator presented and discussed with you the Form FDA 483, Inspectional Observations. We acknowledge receipt of your February 14, 2025, written response to the Form FDA 483.\u003C\u002Fp>\u003Cp>From our review of the FDA Establishment Inspection Report, the documents submitted with that report, and your written response dated February 14, 2025, it appears that you did not adhere to the applicable statutory requirements in the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) and applicable regulations contained in Title 21 of the Code of Federal Regulations, part 312 (21 CFR 312), governing the conduct of clinical investigations and the protection of human subjects.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> We wish to emphasize the following:\u003C\u002Fp>\u003Cp>\u003Cstrong>You failed to ensure that the investigation was conducted according to the investigational plan [21 CFR 312.60].\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>As a clinical investigator, you are required to ensure that your clinical investigations are conducted in accordance with the investigational plan. The investigational plan for Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong> required you to collect safety assessments, including hematology and pulmonary function tests, every week after the first dose of investigational drug in Period I (during the study washout period) and for six weeks after dosing in Period II (that is, on Day 8, Day 15, Day 22, Day 29, Day 35, and Day 42 of each dosing period).\u003C\u002Fp>\u003Cp>You failed to adhere to these requirements. Specifically, for Subjects \u003Cstrong>(b)(6)\u003C\u002Fstrong>, and \u003Cstrong>(b)(6)\u003C\u002Fstrong>, hematology and pulmonary function safety assessments were not completed after investigational drug dosing on Day 8, Day 22, and Day 35 during both Period I and Period II, as required by the protocol. As a result, half of the protocol-required safety assessments for these subjects were not completed during the study.\u003C\u002Fp>\u003Cp>In your February 14, 2025, written response to the Form FDA 483, you stated that you modified the study visit schedule for pragmatic reasons, including subjects’ needs, their travel commitments, and their ongoing treatment plans. You stated that the deviation considered the established late onset of myelosuppression, and that the selection of subjects was based on their historical tolerability of \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You also stated that you employed regular follow-ups, including telephone consultations, to identify and promptly address any adverse events. Furthermore, you stated that this monitoring strategy was tailored to ensure maximum oversight of subject safety, which was discussed and planned during the study initiation visit, and that the sponsor and ethics committee remained aware of these protocol deviations.\u003C\u002Fp>\u003Cp>While we acknowledge your statement that you purposely deviated from the investigational plan to limit protocol-required study visits for pragmatic reasons, and that the sponsor remained aware of these protocol deviations, you did not provide evidence to demonstrate that the sponsor approved of such actions before you deviated from the investigational plan. You also did not provide evidence of the telephone consultations you stated that you employed in regular follow-ups of subjects, to identify and address adverse events.\u003C\u002Fp>\u003Cp>Furthermore, your written response is inadequate because you did not provide information about any completed or proposed corrective actions that would prevent similar violations in the future. For example, you did not provide details about how you will ensure that ongoing and future clinical investigations at your clinical research site will be conducted in compliance with the investigational plan and applicable FDA regulations. Without this information, we are unable to undertake an informed evaluation of your response.\u003C\u002Fp>\u003Cp>We emphasize that, as the clinical investigator, it is your responsibility to ensure that studies are conducted in accordance with the investigational plan, both to protect the rights, safety, and welfare of subjects and to ensure the integrity of study data. The investigational drug, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, may cause subjects to experience certain adverse events, such as myelosuppression, which can lead to fatal infections and bleeding. \u003Cstrong>(b)(4)\u003C\u002Fstrong> may also cause subjects to experience pulmonary toxicity (lung damage), characterized as lung infiltrates and\u002For fibrosis. To minimize these risks, the protocol required hematology and pulmonary function tests to assess subjects’ bone marrow and lung functions at baseline and at weekly safety monitoring visits after the receipt of the investigational drug. Your failure to conduct the study in accordance with the investigational plan – and specifically, your failure to ensure that Subjects \u003Cstrong>(b)(6)\u003C\u002Fstrong>’s bone marrow and lung functions were monitored at the study-required intervals after receiving the investigational drug – raises concerns about your protection of the study subjects enrolled at your site.\u003C\u002Fp>\u003Cp>This letter is not intended to be an all-inclusive list of deficiencies with your clinical study of an investigational drug. It is your responsibility to ensure adherence to each requirement of the law and relevant FDA regulations. You should address any deficiencies and establish procedures to ensure that any ongoing or future studies comply with FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you with an opportunity to address the deficiencies noted above. Within 15 business days of your receipt of this letter, you should notify this office in writing of the actions you have taken to prevent similar violations in the future. Failure to address this matter adequately may lead to regulatory action. If you believe that you have complied with the FD&amp;C Act and relevant regulations, please include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Should you have any questions or concerns about this letter or the inspection, please email FDA at CDER-OSI-Communications@fda.hhs.gov. Your written response and any pertinent documentation should be addressed to:\u003C\u002Fp>\u003Cp>Brittany L. Garr, MPH\u003Cbr>Branch Chief\u003Cbr>Compliance Enforcement Branch\u003Cbr>Division of Enforcement and Postmarketing Safety\u003Cbr>Office of Scientific Investigations\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003Cbr>Building 51, Room 5352\u003Cbr>10903 New Hampshire Avenue\u003Cbr>Silver Spring, MD 20993\u003C\u002Fp>\u003Cp>Sincerely yours,\u003Cbr>{See appended electronic signature page}\u003Cbr>David C. Burrow, Pharm.D., J.D.\u003Cbr>Director\u003Cbr>Office of Scientific Investigations\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\u003Cp>__________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> In accordance with 21 CFR 320.31(c), the provisions of 21 CFR part 312 are applicable to this bioequivalence study because Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong> was conducted under an Investigational New Drug application (IND).\u003Cbr>\u003Cbr>--------------------------------------------------------------------------------------------\u003Cbr>\u003Cstrong>This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.\u003C\u002Fstrong>\u003Cbr>--------------------------------------------------------------------------------------------\u003Cbr>\u002Fs\u002F\u003Cbr>------------------------------------------------------------\u003Cbr>DAVID C BURROW\u003Cbr>12\u002F22\u002F2025 12:05:47 PM\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE AND VIA E-MAIL\n\nReference #:\n\n25-HFD-45-12-03\n\nProduct:\n\nDrugs\n\nRecipient:\n\nPurushothaman Damodara Kumaran, M.D. \u002F Senthil Specialty Hospital\n\nSenthil Specialty Hospital\n\nNumber 10 and 12, Thillai Maistry Street\n\nPondicherry 605001\n\nPuducherry\n\nIndia\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\nFDA Ref. No.: 25-HFD-45-12-03\nDear Dr. Damodara Kumaran:\nThis Warning Letter informs you of objectionable conditions observed during the U.S. Food and Drug Administration (FDA) inspection conducted at Senthil Specialty Hospital in Pondicherry, Puducherry, India, between January 20 and 24, 2025. The investigator representing FDA reviewed your conduct of a clinical in vivo bioequivalence study (Protocol (b)(4), “(b)(4)”) of the investigational drug (b)(4), performed for (b)(4).\nThis inspection was conducted as a part of FDA’s Bioresearch Monitoring Program, which includes inspections designed to evaluate the conduct of research and to help ensure that the rights, safety, and welfare of human subjects have been protected.\nAt the conclusion of the inspection, the FDA investigator presented and discussed with you the Form FDA 483, Inspectional Observations. We acknowledge receipt of your February 14, 2025, written response to the Form FDA 483.\nFrom our review of the FDA Establishment Inspection Report, the documents submitted with that report, and your written response dated February 14, 2025, it appears that you did not adhere to the applicable statutory requirements in the Federal Food, Drug, and Cosmetic Act (FD&C Act) and applicable regulations contained in Title 21 of the Code of Federal Regulations, part 312 (21 CFR 312), governing the conduct of clinical investigations and the protection of human subjects.1 We wish to emphasize the following:\nYou failed to ensure that the investigation was conducted according to the investigational plan [21 CFR 312.60].\nAs a clinical investigator, you are required to ensure that your clinical investigations are conducted in accordance with the investigational plan. The investigational plan for Protocol (b)(4) required you to collect safety assessments, including hematology and pulmonary function tests, every week after the first dose of investigational drug in Period I (during the study washout period) and for six weeks after dosing in Period II (that is, on Day 8, Day 15, Day 22, Day 29, Day 35, and Day 42 of each dosing period).\nYou failed to adhere to these requirements. Specifically, for Subjects (b)(6), and (b)(6), hematology and pulmonary function safety assessments were not completed after investigational drug dosing on Day 8, Day 22, and Day 35 during both Period I and Period II, as required by the protocol. As a result, half of the protocol-required safety assessments for these subjects were not completed during the study.\nIn your February 14, 2025, written response to the Form FDA 483, you stated that you modified the study visit schedule for pragmatic reasons, including subjects’ needs, their travel commitments, and their ongoing treatment plans. You stated that the deviation considered the established late onset of myelosuppression, and that the selection of subjects was based on their historical tolerability of (b)(4). You also stated that you employed regular follow-ups, including telephone consultations, to identify and promptly address any adverse events. Furthermore, you stated that this monitoring strategy was tailored to ensure maximum oversight of subject safety, which was discussed and planned during the study initiation visit, and that the sponsor and ethics committee remained aware of these protocol deviations.\nWhile we acknowledge your statement that you purposely deviated from the investigational plan to limit protocol-required study visits for pragmatic reasons, and that the sponsor remained aware of these protocol deviations, you did not provide evidence to demonstrate that the sponsor approved of such actions before you deviated from the investigational plan. You also did not provide evidence of the telephone consultations you stated that you employed in regular follow-ups of subjects, to identify and address adverse events.\nFurthermore, your written response is inadequate because you did not provide information about any completed or proposed corrective actions that would prevent similar violations in the future. For example, you did not provide details about how you will ensure that ongoing and future clinical investigations at your clinical research site will be conducted in compliance with the investigational plan and applicable FDA regulations. Without this information, we are unable to undertake an informed evaluation of your response.\nWe emphasize that, as the clinical investigator, it is your responsibility to ensure that studies are conducted in accordance with the investigational plan, both to protect the rights, safety, and welfare of subjects and to ensure the integrity of study data. The investigational drug, (b)(4), may cause subjects to experience certain adverse events, such as myelosuppression, which can lead to fatal infections and bleeding. (b)(4) may also cause subjects to experience pulmonary toxicity (lung damage), characterized as lung infiltrates and\u002For fibrosis. To minimize these risks, the protocol required hematology and pulmonary function tests to assess subjects’ bone marrow and lung functions at baseline and at weekly safety monitoring visits after the receipt of the investigational drug. Your failure to conduct the study in accordance with the investigational plan – and specifically, your failure to ensure that Subjects (b)(6)’s bone marrow and lung functions were monitored at the study-required intervals after receiving the investigational drug – raises concerns about your protection of the study subjects enrolled at your site.\nThis letter is not intended to be an all-inclusive list of deficiencies with your clinical study of an investigational drug. It is your responsibility to ensure adherence to each requirement of the law and relevant FDA regulations. You should address any deficiencies and establish procedures to ensure that any ongoing or future studies comply with FDA regulations.\nThis letter notifies you of our findings and provides you with an opportunity to address the deficiencies noted above. Within 15 business days of your receipt of this letter, you should notify this office in writing of the actions you have taken to prevent similar violations in the future. Failure to address this matter adequately may lead to regulatory action. If you believe that you have complied with the FD&C Act and relevant regulations, please include your reasoning and any supporting information for our consideration.\nShould you have any questions or concerns about this letter or the inspection, please email FDA at CDER-OSI-Communications@fda.hhs.gov. Your written response and any pertinent documentation should be addressed to:\nBrittany L. Garr, MPH\nBranch Chief\nCompliance Enforcement Branch\nDivision of Enforcement and Postmarketing Safety\nOffice of Scientific Investigations\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\nBuilding 51, Room 5352\n10903 New Hampshire Avenue\nSilver Spring, MD 20993\nSincerely yours,\n{See appended electronic signature page}\nDavid C. Burrow, Pharm.D., J.D.\nDirector\nOffice of Scientific Investigations\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\n__________________\n1 In accordance with 21 CFR 320.31(c), the provisions of 21 CFR part 312 are applicable to this bioequivalence study because Protocol (b)(4) was conducted under an Investigational New Drug application (IND).\n\n--------------------------------------------------------------------------------------------\nThis is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.\n--------------------------------------------------------------------------------------------\n\u002Fs\u002F\n------------------------------------------------------------\nDAVID C BURROW\n12\u002F22\u002F2025 12:05:47 PM","Purushothaman Damodara Kumaran, M.D. \u002F Senthil Specialty Hospital","purushothaman-damodara-kumaran-md-senthil-specialty-hospital-721325-12222025","2026-08-18T06:42:28.498414+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fpurushothaman-damodara-kumaran-md-senthil-specialty-hospital-721325-12222025","2026-10-26T08:09:45.862611+00:00","2026-01-13","721325","2026-08-19T07:18:11.533+00:00","VIA UNITED PARCEL SERVICE AND VIA E-MAIL","25-HFD-45-12-03","2025-12-22",{"id":77,"raw":78,"subject":83,"body_html":84,"body_text":85,"firm_name":86,"letter_id":87,"created_at":88,"fei_number":20,"letter_url":89,"updated_at":90,"action_type":23,"case_status":48,"posted_date":91,"marcs_cms_no":92,"product_type":27,"closeout_date":20,"issuing_office":82,"recipient_name":93,"body_fetched_at":94,"delivery_method":95,"recipient_title":20,"reference_number":20,"action_taken_date":96,"medical_device_id":20,"response_letter_date":20},2240,[79,80,81,82,83,13,13,13],"\u003Ctime datetime=\"2023-01-24T14:20:00Z\">01\u002F24\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-01-11T05:00:00Z\">01\u002F11\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Flarkin-community-hospital-institutional-review-board-638146-01112023\">Larkin Community Hospital Institutional Review Board\u003C\u002Fa>","Center for Drug Evaluation and Research | CDER","Bioresearch Monitoring Program\u002FInstitutional Review Board (IRB)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>(b)(6)\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Vice President for Research and Academic Affairs\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Larkin Community Hospital Institutional Review Board\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>7031 Southwest 62nd Avenue\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>South Miami\u003C\u002Fspan>, \u003Cspan>FL\u003C\u002Fspan> \u003Cspan>33143-4701\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>January 11, 2023\u003C\u002Fp>\n\n\u003Cp>FDA Ref. No.: 23-HFD-45-01-01\u003C\u002Fp>\n\n\u003Cp>Dear \u003Cstrong>(b)(6)\u003C\u002Fstrong>:\u003C\u002Fp>\n\n\u003Cp>This Warning Letter informs you of objectionable conditions observed during the U.S. Food and Drug Administration (FDA) inspection conducted between November 12 and November 19, 2021, of the Larkin Community Hospital Institutional Review Board (IRB). Investigator Richard A. Lyght, representing FDA, conducted the inspection to determine whether the IRB’s procedures for the protection of human subjects complied with FDA regulations contained in Title 21 of the Code of Federal Regulations (CFR), parts 50 and 56. These regulations apply to clinical investigations of products regulated by FDA.\u003C\u002Fp>\n\n\u003Cp>This inspection is a part of FDA’s Bioresearch Monitoring Program, which includes inspections designed to evaluate the conduct of research and to help ensure that the rights, safety, and welfare of human subjects have been protected.\u003C\u002Fp>\n\n\u003Cp>At the conclusion of the inspection, Investigator Lyght presented and discussed with you Form FDA 483, Inspectional Observations. We acknowledge receipt of the IRB’s December 6, 2021, written response to the Form FDA 483.\u003C\u002Fp>\n\n\u003Cp>From our review of the FDA Establishment Inspection Report, the documents submitted with that report, and the IRB’s December 6, 2021, written response, it appears that the IRB did not adhere to applicable statutory requirements in the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) and FDA regulations governing the protection of human subjects.\u003C\u002Fp>\n\n\u003Cp>We wish to emphasize the following:\u003Cbr>\n\u003Cbr>\n\u003Cstrong>1. The IRB failed to review proposed research at convened meetings at which a majority of the members of the IRB are present, including at least one member whose primary concerns are in nonscientific areas [21 CFR 56.108(c)].\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Under 21 CFR 56.108(c), except when an expedited review procedure is used, the IRB may review proposed research only at convened meetings at which a majority of the IRB members are present, including at least one member whose primary concerns are in nonscientific areas. The IRB failed to adhere to this requirement.\u003C\u002Fp>\n\n\u003Cp>Specifically, the IRB reviewed and approved FDA-regulated research at convened IRB meetings where a majority of the IRB members, including at least one nonscientist member, were not present.\u003C\u002Fp>\n\n\u003Cp>IRB meeting minutes for meetings held on April 24, 2020; August 3, 2020; September 11, 2020; November 16, 2020; and February 15, 2021, indicate that the following members were present, and that no member whose primary concerns are in nonscientific areas attended:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>IRB meeting held on April 24, 2020: Gerardo Ferrer (physician), \u003Cstrong>(b)(6)\u003C\u002Fstrong> (pharmacist), \u003Cstrong>(b)(6)\u003C\u002Fstrong> (physician), and \u003Cstrong>(b)(6)\u003C\u002Fstrong> (pharmacist)\u003C\u002Fli>\n\t\u003Cli>IRB meeting held on August 3, 2020: Gerardo F. Ferrer (physician), \u003Cstrong>(b)(6)\u003C\u002Fstrong> (pharmacist), \u003Cstrong>(b)(6)\u003C\u002Fstrong> (physician), and \u003Cstrong>(b)(6)\u003C\u002Fstrong> (pharmacist)\u003C\u002Fli>\n\t\u003Cli>IRB meeting held on September 11, 2020: Gerardo F. Ferrer (physician), \u003Cstrong>(b)(6)\u003C\u002Fstrong> (pharmacist), \u003Cstrong>(b)(6)\u003C\u002Fstrong> (physician), \u003Cstrong>(b)(6)\u003C\u002Fstrong> (physician), and \u003Cstrong>(b)(6)\u003C\u002Fstrong> (pharmacist)\u003C\u002Fli>\n\t\u003Cli>IRB meeting held on November 16, 2020: \u003Cstrong>(b)(6)\u003C\u002Fstrong> (pharmacist), \u003Cstrong>(b)(6)\u003C\u002Fstrong> (physician), \u003Cstrong>(b)(6)\u003C\u002Fstrong> (physician), and \u003Cstrong>(b)(6)\u003C\u002Fstrong> (pharmacist)\u003C\u002Fli>\n\t\u003Cli>IRB meeting held on February 15, 2021: Gerardo F. Ferrer (physician), \u003Cstrong>(b)(6)\u003C\u002Fstrong> (pharmacist), \u003Cstrong>(b)(6)\u003C\u002Fstrong> (physician), \u003Cstrong>(b)(6)\u003C\u002Fstrong> (physician), and \u003Cstrong>(b)(6)\u003C\u002Fstrong> (pharmacist)\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>The IRB should not have reviewed or approved the proposed research because the IRB did not have a member present whose primary concerns are in nonscientific areas at these IRB meetings in which FDA-regulated research was reviewed.\u003C\u002Fp>\n\n\u003Cp>During the inspection, the IRB chair, Gerardo F. Ferrer, M.D., indicated that \u003Cstrong>(b)(6)\u003C\u002Fstrong> acted as the nonscientific IRB member. However, Ms. \u003Cstrong>(b)(6)\u003C\u002Fstrong> resigned on April 24, 2020, and was not in attendance at any of the above-mentioned IRB meetings. Furthermore, no other nonscientific member appears to have been identified or attended any of the above-mentioned IRB meetings.\u003C\u002Fp>\n\n\u003Cp>In your December 6, 2021, written response to the Form FDA 483, you indicated that this observation has been noted and procedures are being initiated to correct this observation. In addition, you indicated that IRB meetings will only take place if a majority of the IRB members are available, including one nonscientific member. You also stated that the IRB minute agendas will document members’ affiliations to facilitate audit review designation.\u003C\u002Fp>\n\n\u003Cp>We are unable to perform an informed evaluation of the IRB’s written response because you did not provide a corrective action plan that, if properly carried out, would prevent the recurrence of this type of violation in the future. Specifically, you did not provide sufficient details on the procedures you are initiating and how you will ensure that a majority of the IRB members, including at least one member whose primary concerns are in nonscientific areas, will be present at convened meetings when proposed FDA-regulated research is under review.\u003C\u002Fp>\n\n\u003Cp>As an IRB, review of proposed research at convened meetings at which a majority of the IRB members is present, including at least one member whose primary concerns are in a nonscientific area, is important to ensure that the IRB’s review and approval of research is fair and equitable.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. The IRB failed to prepare and maintain adequate documentation of IRB activities, including a list of IRB members [21 CFR 56.115(a)(5)].\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Under 21 CFR 56.115(a), the IRB is required to prepare and maintain adequate documentation of IRB activities, including a list of IRB members identified by name; earned degrees; representative capacity; indications of experience such as board certifications, licenses, etc., sufficient to describe each member’s chief anticipated contributions to IRB deliberations; and any employment or other relationship between each member and the institution. The IRB failed to adhere to these requirements.\u003C\u002Fp>\n\n\u003Cp>Specifically, the IRB failed to prepare and maintain a list of IRB members, in accordance with 21 CFR 56.115(a)(5), for the time period between July 2019 and March 2021. During the inspection, the IRB compiled a membership list for this time frame. However, this list is inadequate because it did not include all IRB members listed in minutes for IRB meetings convened during this time frame. Furthermore, for several listed IRB members, the list did not include each IRB member’s representative capacity, indications of experience sufficient to describe the member’s chief anticipated contributions to the IRB deliberations, or any employment or other relationship between the member and the institution. For example:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>\u003Cstrong>(b)(6)\u003C\u002Fstrong>, M.D., M.B.A., F.A.C.S., is not listed on this membership list, but is listed as a voting member in the minutes of the IRB meetings held on September 11, 2020; November 16, 2020; and February 15, 2021.\u003C\u002Fli>\n\t\u003Cli>\u003Cstrong>(b)(6)\u003C\u002Fstrong>, M.S., L.M.H.C., C.A.P., is not listed on this membership list, but is listed as an absent voting member in the minutes of the IRB meetings held on April 24, 2020; August 3, 2020; September 11, 2020; and February 15, 2021.\u003C\u002Fli>\n\t\u003Cli>\u003Cstrong>(b)(6)\u003C\u002Fstrong>, M.D., M.S.S., is listed on this membership list, but this IRB member’s representative capacity is missing.\u003C\u002Fli>\n\t\u003Cli>\u003Cstrong>(b)(6)\u003C\u002Fstrong>, Pharm.D., M.P.H., B.C.P.S., is listed on this membership list, but this IRB member’s representative capacity is missing.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>In your December 6, 2021, written response to the Form FDA 483, you noted the observation and stated that it was difficult to acquire in full details the complete membership list because the prior IRB coordinator’s files were not easily accessible. You noted that a new roster of current members will be created, maintained, monitored annually, and adjusted when required. You also indicated that the membership list will include the full details of each member’s name, earned degrees, representative capacity, and indication of experience sufficient to describe the member’s chief anticipated contribution to IRB deliberations. However, we note that this membership list, as proposed, would not meet the regulatory requirements unless employment or other relationship between each member and the institution were to be included, as required under 21 CFR 56.115(a)(5).\u003C\u002Fp>\n\n\u003Cp>We are unable to undertake an informed evaluation of the IRB’s written response because you did not provide a corrective action plan that, if properly carried out, would prevent the recurrence of this type of violation in the future. Specifically, you did not provide sufficient details on the actions that will be taken (for example, maintaining and monitoring the new membership list annually) to ensure that the IRB prepares and maintains a list of IRB members in accordance with the regulations at 21 CFR 56.115(a)(5). In addition, you did not provide documentation of a complete, updated membership list that includes the missing information described above. Please submit a current membership list that complies with 21 CFR 56.115(a)(5).\u003C\u002Fp>\n\n\u003Cp>As an IRB, you are required to prepare and maintain a complete list of IRB members in compliance with 21 CFR 56.115(a)(5) to ensure that the IRB has adequate representation, experience, and expertise to promote complete and adequate review of the institution’s research activities.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. The IRB failed to ensure that information given to subjects as part of informed consent is in accordance with 21 CFR part 50.25 [21 CFR 56.109(b)].\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Under 21 CFR 56.109(b), the IRB must require that information given to subjects as part of the informed consent process is in accordance with 21 CFR 50.25 (elements of informed consent). The IRB failed to ensure that the IRB-approved informed consent documents (ICDs) for the following two clinical trials, which meet the definition of an “applicable drug clinical trial”\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>, contained the statement\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> notifying the subject that clinical trial information has been or will be submitted for inclusion in the clinical trial registry databank, as required by 21 CFR 50.25(c):\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Protocol LCH-2-112020, “Impact of GSE and Xylitol (Xlear) in Symptoms and time to PCR negativisation of patients with Acute COVID-19 Infection”\u003C\u002Fli>\n\t\u003Cli>Protocol LCH-3-082020, “A Randomized Placebo Control Trial to Evaluate the Efficacy of Xylitol Nasal Sprays vs. Placebo for Acute COVID-19 Infection”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>In your December 6, 2021, written response, you noted the observation and stated that actions were in motion to establish best practices. You also indicated that the formatted informed consent will contain the statement for clinical trials, as required by 21 CFR 50.25(c).\u003C\u002Fp>\n\n\u003Cp>We acknowledge your written response, indicating that “actions are in motion to establish best practice” and that ICDs will contain the required information. However, we are unable to perform an informed evaluation of the IRB’s written response because you did not provide a corrective action plan that, if properly carried out, would prevent the recurrence of this type of violation in the future. Specifically, you did not provide sufficient details on the best practices you are establishing and how you will ensure that the ICDs will contain the statement, as required by 21 CFR 50.25(c), when appropriate.\u003C\u002Fp>\n\n\u003Cp>Failure to ensure that IRB-approved informed consent documents for applicable clinical trials contain the statement notifying subjects that clinical trial information has been or will be submitted for inclusion in the clinical trial registry databank may result in subjects not being provided appropriate human subject research protections or pertinent information about the clinical investigation.\u003C\u002Fp>\n\n\u003Cp>For more information on this element, please see “Guidance for Sponsors, Investigators, and Institutional Review Boards: Questions and Answers on Informed Consent Elements, 21 CFR § 50.25(c)” at the following URL:&nbsp;\u003Ca href=\"http:\u002F\u002Fwww.fda.gov\u002Fdownloads\u002FRegulatoryInformation\u002FGuidances\u002FUCM291085.pdf\">http:\u002F\u002Fwww.fda.gov\u002Fdownloads\u002FRegulatoryInformation\u002FGuidances\u002FUCM291085.pdf\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive list of deficiencies related to the IRB’s procedures or the review and approval by the IRB of protocols and informed consent documents. It is the IRB’s responsibility to ensure adherence to each requirement of the law and relevant FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. Within 15 business days of your receipt of this letter, you should notify this office in writing of the actions the IRB plans to take or has taken to address any violations and to prevent recurrence of similar violations in the future. Failure to adequately address this matter may lead to regulatory action. If you believe you have complied with the FD&amp;C Act and relevant regulations, please include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>We recommend that the IRB visit the following FDA Web page for information on human subject protections that may assist the IRB in its efforts to come into compliance with FDA regulations:&nbsp;\u003Ca href=\"http:\u002F\u002Fwww.fda.gov\u002FScienceResearch\u002FSpecialTopics\u002FRunningClinicalTrials\u002Fdefault.htm\">http:\u002F\u002Fwww.fda.gov\u002FScienceResearch\u002FSpecialTopics\u002FRunningClinicalTrials\u002Fdefault.htm\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>If the IRB has any questions, please call Miah Jung, Pharm.D., M.S., at 240-402-3728. Alternatively, you may e-mail FDA at CDER-OSI-Communications@fda.hhs.gov. The IRB’s written response and any pertinent documentation should be addressed to:\u003C\u002Fp>\n\n\u003Cp>Miah Jung, Pharm.D., M.S.\u003Cbr>\nBranch Chief\u003Cbr>\nCompliance Enforcement Branch\u003Cbr>\nDivision of Enforcement and Postmarketing Safety\u003Cbr>\nOffice of Scientific Investigations\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nU.S. Food and Drug Administration\u003Cbr>\nBuilding 51, Room 5352\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993\u003C\u002Fp>\n\n\u003Cp>Sincerely yours,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>David C. Burrow, Pharm.D., J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Scientific Investigations\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nU.S. Food and Drug Administration\u003C\u002Fp>\n\n\u003Cp>__________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> See 42 USC 282(j)(1)(A) and 42 CFR 11.10 for the definition of “applicable drug clinical trial.”\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> “A description of this clinical trial will be available on http:\u002F\u002Fwww.ClinicalTrials.gov, as required by U.S. Law. This Web site will not include information that can identify you. At most, the Web site will include a summary of the results. You can search this Web site at any time.”\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\n(b)(6)\n\nRecipient Title\n\nVice President for Research and Academic Affairs\n\nLarkin Community Hospital Institutional Review Board\n\n7031 Southwest 62nd Avenue\n\nSouth Miami, FL 33143-4701\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWARNING LETTER\n\nJanuary 11, 2023\n\nFDA Ref. No.: 23-HFD-45-01-01\n\nDear (b)(6):\n\nThis Warning Letter informs you of objectionable conditions observed during the U.S. Food and Drug Administration (FDA) inspection conducted between November 12 and November 19, 2021, of the Larkin Community Hospital Institutional Review Board (IRB). Investigator Richard A. Lyght, representing FDA, conducted the inspection to determine whether the IRB’s procedures for the protection of human subjects complied with FDA regulations contained in Title 21 of the Code of Federal Regulations (CFR), parts 50 and 56. These regulations apply to clinical investigations of products regulated by FDA.\n\nThis inspection is a part of FDA’s Bioresearch Monitoring Program, which includes inspections designed to evaluate the conduct of research and to help ensure that the rights, safety, and welfare of human subjects have been protected.\n\nAt the conclusion of the inspection, Investigator Lyght presented and discussed with you Form FDA 483, Inspectional Observations. We acknowledge receipt of the IRB’s December 6, 2021, written response to the Form FDA 483.\n\nFrom our review of the FDA Establishment Inspection Report, the documents submitted with that report, and the IRB’s December 6, 2021, written response, it appears that the IRB did not adhere to applicable statutory requirements in the Federal Food, Drug, and Cosmetic Act (FD&C Act) and FDA regulations governing the protection of human subjects.\n\nWe wish to emphasize the following:\n\n1. The IRB failed to review proposed research at convened meetings at which a majority of the members of the IRB are present, including at least one member whose primary concerns are in nonscientific areas [21 CFR 56.108(c)].\n\nUnder 21 CFR 56.108(c), except when an expedited review procedure is used, the IRB may review proposed research only at convened meetings at which a majority of the IRB members are present, including at least one member whose primary concerns are in nonscientific areas. The IRB failed to adhere to this requirement.\n\nSpecifically, the IRB reviewed and approved FDA-regulated research at convened IRB meetings where a majority of the IRB members, including at least one nonscientist member, were not present.\n\nIRB meeting minutes for meetings held on April 24, 2020; August 3, 2020; September 11, 2020; November 16, 2020; and February 15, 2021, indicate that the following members were present, and that no member whose primary concerns are in nonscientific areas attended:\n\nIRB meeting held on April 24, 2020: Gerardo Ferrer (physician), (b)(6) (pharmacist), (b)(6) (physician), and (b)(6) (pharmacist)\n\nIRB meeting held on August 3, 2020: Gerardo F. Ferrer (physician), (b)(6) (pharmacist), (b)(6) (physician), and (b)(6) (pharmacist)\n\nIRB meeting held on September 11, 2020: Gerardo F. Ferrer (physician), (b)(6) (pharmacist), (b)(6) (physician), (b)(6) (physician), and (b)(6) (pharmacist)\n\nIRB meeting held on November 16, 2020: (b)(6) (pharmacist), (b)(6) (physician), (b)(6) (physician), and (b)(6) (pharmacist)\n\nIRB meeting held on February 15, 2021: Gerardo F. Ferrer (physician), (b)(6) (pharmacist), (b)(6) (physician), (b)(6) (physician), and (b)(6) (pharmacist)\n\nThe IRB should not have reviewed or approved the proposed research because the IRB did not have a member present whose primary concerns are in nonscientific areas at these IRB meetings in which FDA-regulated research was reviewed.\n\nDuring the inspection, the IRB chair, Gerardo F. Ferrer, M.D., indicated that (b)(6) acted as the nonscientific IRB member. However, Ms. (b)(6) resigned on April 24, 2020, and was not in attendance at any of the above-mentioned IRB meetings. Furthermore, no other nonscientific member appears to have been identified or attended any of the above-mentioned IRB meetings.\n\nIn your December 6, 2021, written response to the Form FDA 483, you indicated that this observation has been noted and procedures are being initiated to correct this observation. In addition, you indicated that IRB meetings will only take place if a majority of the IRB members are available, including one nonscientific member. You also stated that the IRB minute agendas will document members’ affiliations to facilitate audit review designation.\n\nWe are unable to perform an informed evaluation of the IRB’s written response because you did not provide a corrective action plan that, if properly carried out, would prevent the recurrence of this type of violation in the future. Specifically, you did not provide sufficient details on the procedures you are initiating and how you will ensure that a majority of the IRB members, including at least one member whose primary concerns are in nonscientific areas, will be present at convened meetings when proposed FDA-regulated research is under review.\n\nAs an IRB, review of proposed research at convened meetings at which a majority of the IRB members is present, including at least one member whose primary concerns are in a nonscientific area, is important to ensure that the IRB’s review and approval of research is fair and equitable.\n\n2. The IRB failed to prepare and maintain adequate documentation of IRB activities, including a list of IRB members [21 CFR 56.115(a)(5)].\n\nUnder 21 CFR 56.115(a), the IRB is required to prepare and maintain adequate documentation of IRB activities, including a list of IRB members identified by name; earned degrees; representative capacity; indications of experience such as board certifications, licenses, etc., sufficient to describe each member’s chief anticipated contributions to IRB deliberations; and any employment or other relationship between each member and the institution. The IRB failed to adhere to these requirements.\n\nSpecifically, the IRB failed to prepare and maintain a list of IRB members, in accordance with 21 CFR 56.115(a)(5), for the time period between July 2019 and March 2021. During the inspection, the IRB compiled a membership list for this time frame. However, this list is inadequate because it did not include all IRB members listed in minutes for IRB meetings convened during this time frame. Furthermore, for several listed IRB members, the list did not include each IRB member’s representative capacity, indications of experience sufficient to describe the member’s chief anticipated contributions to the IRB deliberations, or any employment or other relationship between the member and the institution. For example:\n\n(b)(6), M.D., M.B.A., F.A.C.S., is not listed on this membership list, but is listed as a voting member in the minutes of the IRB meetings held on September 11, 2020; November 16, 2020; and February 15, 2021.\n\n(b)(6), M.S., L.M.H.C., C.A.P., is not listed on this membership list, but is listed as an absent voting member in the minutes of the IRB meetings held on April 24, 2020; August 3, 2020; September 11, 2020; and February 15, 2021.\n\n(b)(6), M.D., M.S.S., is listed on this membership list, but this IRB member’s representative capacity is missing.\n\n(b)(6), Pharm.D., M.P.H., B.C.P.S., is listed on this membership list, but this IRB member’s representative capacity is missing.\n\nIn your December 6, 2021, written response to the Form FDA 483, you noted the observation and stated that it was difficult to acquire in full details the complete membership list because the prior IRB coordinator’s files were not easily accessible. You noted that a new roster of current members will be created, maintained, monitored annually, and adjusted when required. You also indicated that the membership list will include the full details of each member’s name, earned degrees, representative capacity, and indication of experience sufficient to describe the member’s chief anticipated contribution to IRB deliberations. However, we note that this membership list, as proposed, would not meet the regulatory requirements unless employment or other relationship between each member and the institution were to be included, as required under 21 CFR 56.115(a)(5).\n\nWe are unable to undertake an informed evaluation of the IRB’s written response because you did not provide a corrective action plan that, if properly carried out, would prevent the recurrence of this type of violation in the future. Specifically, you did not provide sufficient details on the actions that will be taken (for example, maintaining and monitoring the new membership list annually) to ensure that the IRB prepares and maintains a list of IRB members in accordance with the regulations at 21 CFR 56.115(a)(5). In addition, you did not provide documentation of a complete, updated membership list that includes the missing information described above. Please submit a current membership list that complies with 21 CFR 56.115(a)(5).\n\nAs an IRB, you are required to prepare and maintain a complete list of IRB members in compliance with 21 CFR 56.115(a)(5) to ensure that the IRB has adequate representation, experience, and expertise to promote complete and adequate review of the institution’s research activities.\n\n3. The IRB failed to ensure that information given to subjects as part of informed consent is in accordance with 21 CFR part 50.25 [21 CFR 56.109(b)].\n\nUnder 21 CFR 56.109(b), the IRB must require that information given to subjects as part of the informed consent process is in accordance with 21 CFR 50.25 (elements of informed consent). The IRB failed to ensure that the IRB-approved informed consent documents (ICDs) for the following two clinical trials, which meet the definition of an “applicable drug clinical trial”1, contained the statement2 notifying the subject that clinical trial information has been or will be submitted for inclusion in the clinical trial registry databank, as required by 21 CFR 50.25(c):\n\nProtocol LCH-2-112020, “Impact of GSE and Xylitol (Xlear) in Symptoms and time to PCR negativisation of patients with Acute COVID-19 Infection”\n\nProtocol LCH-3-082020, “A Randomized Placebo Control Trial to Evaluate the Efficacy of Xylitol Nasal Sprays vs. Placebo for Acute COVID-19 Infection”\n\nIn your December 6, 2021, written response, you noted the observation and stated that actions were in motion to establish best practices. You also indicated that the formatted informed consent will contain the statement for clinical trials, as required by 21 CFR 50.25(c).\n\nWe acknowledge your written response, indicating that “actions are in motion to establish best practice” and that ICDs will contain the required information. However, we are unable to perform an informed evaluation of the IRB’s written response because you did not provide a corrective action plan that, if properly carried out, would prevent the recurrence of this type of violation in the future. Specifically, you did not provide sufficient details on the best practices you are establishing and how you will ensure that the ICDs will contain the statement, as required by 21 CFR 50.25(c), when appropriate.\n\nFailure to ensure that IRB-approved informed consent documents for applicable clinical trials contain the statement notifying subjects that clinical trial information has been or will be submitted for inclusion in the clinical trial registry databank may result in subjects not being provided appropriate human subject research protections or pertinent information about the clinical investigation.\n\nFor more information on this element, please see “Guidance for Sponsors, Investigators, and Institutional Review Boards: Questions and Answers on Informed Consent Elements, 21 CFR § 50.25(c)” at the following URL: http:\u002F\u002Fwww.fda.gov\u002Fdownloads\u002FRegulatoryInformation\u002FGuidances\u002FUCM291085.pdf.\n\nThis letter is not intended to be an all-inclusive list of deficiencies related to the IRB’s procedures or the review and approval by the IRB of protocols and informed consent documents. It is the IRB’s responsibility to ensure adherence to each requirement of the law and relevant FDA regulations.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. Within 15 business days of your receipt of this letter, you should notify this office in writing of the actions the IRB plans to take or has taken to address any violations and to prevent recurrence of similar violations in the future. Failure to adequately address this matter may lead to regulatory action. If you believe you have complied with the FD&C Act and relevant regulations, please include your reasoning and any supporting information for our consideration.\n\nWe recommend that the IRB visit the following FDA Web page for information on human subject protections that may assist the IRB in its efforts to come into compliance with FDA regulations: http:\u002F\u002Fwww.fda.gov\u002FScienceResearch\u002FSpecialTopics\u002FRunningClinicalTrials\u002Fdefault.htm.\n\nIf the IRB has any questions, please call Miah Jung, Pharm.D., M.S., at 240-402-3728. Alternatively, you may e-mail FDA at CDER-OSI-Communications@fda.hhs.gov. The IRB’s written response and any pertinent documentation should be addressed to:\n\nMiah Jung, Pharm.D., M.S.\n\nBranch Chief\n\nCompliance Enforcement Branch\n\nDivision of Enforcement and Postmarketing Safety\n\nOffice of Scientific Investigations\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nU.S. Food and Drug Administration\n\nBuilding 51, Room 5352\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993\n\nSincerely yours,\n\n\u002FS\u002F\n\nDavid C. Burrow, Pharm.D., J.D.\n\nDirector\n\nOffice of Scientific Investigations\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nU.S. Food and Drug Administration\n\n__________________________\n\n1 See 42 USC 282(j)(1)(A) and 42 CFR 11.10 for the definition of “applicable drug clinical trial.”\n\n2 “A description of this clinical trial will be available on http:\u002F\u002Fwww.ClinicalTrials.gov, as required by U.S. Law. This Web site will not include information that can identify you. At most, the Web site will include a summary of the results. You can search this Web site at any time.”","Larkin Community Hospital Institutional Review Board","larkin-community-hospital-institutional-review-board-638146-01112023","2026-08-18T06:42:29.145918+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Flarkin-community-hospital-institutional-review-board-638146-01112023","2026-10-26T08:09:12.420022+00:00","2023-01-24","638146","(b)(6)","2026-08-20T01:18:23.294+00:00","VIA UNITED PARCEL SERVICE","2023-01-11",{"id":98,"raw":99,"subject":103,"body_html":104,"body_text":105,"firm_name":106,"letter_id":107,"created_at":108,"fei_number":20,"letter_url":109,"updated_at":110,"action_type":23,"case_status":48,"posted_date":111,"marcs_cms_no":112,"product_type":27,"closeout_date":20,"issuing_office":82,"recipient_name":113,"body_fetched_at":114,"delivery_method":115,"recipient_title":20,"reference_number":20,"action_taken_date":116,"medical_device_id":20,"response_letter_date":20},3474,[100,101,102,82,103,13,13,13],"\u003Ctime datetime=\"2021-03-09T14:20:00Z\">03\u002F09\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-03-01T05:00:00Z\">03\u002F01\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgaza-proveedora-de-servicios-de-hospedaje-y-alimentacion-611881-03012021\">Gaza Proveedora De Servicios De Hospedaje Y Alimentacion\u003C\u002Fa>","Finished Pharmaceuticals\u002FUnapproved New Drug\u002FMisbranded\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Luis Armando Garcia Olivares\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Gaza Proveedora De Servicios De Hospedaje Y Alimentacion\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Calle Castille 1473-A Colonia Jardines de la Reyna\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>45410\u003C\u002Fspan> \u003Cspan>Tonala\u003C\u002Fspan>, \u003Cspan>Jal.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Mexico\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter 320-21-31\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>March 01, 2021\u003Cbr>\n\u003Cbr>\nDear Mr. Olivares:\u003C\u002Fp>\n\n\u003Cp>Your firm was recently registered as a human drug manufacturer. The U.S. Food and Drug Administration (FDA) conducted testing of a consumer antiseptic hand rub drug product (also referred to as a consumer hand sanitizer) labeled as Pristine Hand Sanitizer Gel. This drug product was labeled as manufactured at your facility, Gaza Proveedora De Servicios De Hospedaje Y Alimentacion, FEI 3016808324, at Calle Castille 1473-A Colonia Jardines de la Reyna, Tonala, Jalisco, Mexico. Following an attempt to import Pristine Hand Sanitizer Gel into the United States, it was detained and refused admission at the border.\u003C\u002Fp>\n\n\u003Cp>The results of FDA laboratory testing of a batch of this product detained at the border demonstrate that this drug product labeled as manufactured at your facility is adulterated within the meaning of section 501(c) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act or Act), 21 U.S.C. 351(c), in that its strength, purity, or quality falls below that which it purports or is represented to possess. In addition, this product is adulterated within the meaning of section 501(a)(2)(B) of the FD&amp;C Act (21 U.S.C. 351(a)(2)(B)), in that the subpotency demonstrates that the quality assurance within your facility is not functioning in accordance with Current Good Manufacturing Practice (CGMP) requirements.\u003C\u002Fp>\n\n\u003Cp>In addition, Pristine Hand Sanitizer Gel drug product is an unapproved new drug introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a), and is misbranded under sections 502(a) and (ee) of the FD&amp;C Act, 21 U.S.C. 352(a) and (ee). Introduction or delivery for introduction of such a product into interstate commerce is prohibited under sections 301(d) and (a) of the FD&amp;C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Adulteration Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Pristine Hand Sanitizer Gel, labeled as manufactured at your facility, is labeled to contain 68% volume\u002Fvolume (v\u002Fv) of the active ingredient alcohol ethyl alcohol (ethanol). However, FDA laboratory testing of a batch of this product detained at the border found that the drug product contained an average of only 42% v\u002Fv ethanol. This hand sanitizer drug product is adulterated under section 501(c) of the FD&amp;C Act in that the active ingredient of ethanol is present at levels in the product lower than that which is declared on its label.\u003C\u002Fp>\n\n\u003Cp>CDC recommends\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> that, if soap and water are not readily available, consumers use an alcohol-based hand sanitizer that contains not less than 60% alcohol (ethanol). This is the minimum active ingredient concentration of ethanol specified in the 1994 Tentative Final Monograph for Health-Care Antiseptic Drug Products (59 FR 31402), as further amended by “Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Proposed Amendment of the Tentative Final Monograph; Reopening of Administrative Record,” Proposed Rule, 81 FR 42912 (June 30, 2016).\u003C\u002Fp>\n\n\u003Cp>On November 20, 2020, FDA held a teleconference with your registered U.S. Agent, Eport USA, LLC, but your firm did not attend. We recommended to your U.S. agent that you consider removing all of your firm’s hand sanitizer drug products currently in distribution to the U.S. market.\u003C\u002Fp>\n\n\u003Cp>On November 20, 2020 FDA notified the public of the subpotency of your hand sanitizer drug product at the following website: \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-updates-hand-sanitizers-consumers-should-not-use\">https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-updates-hand-sanitizers-consumers-should-not-use\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>You issued a voluntary nationwide recall of Pristine Hand Sanitizer Gel and Zapien Productos Hand Sanitizer Gel within expiry that was distributed in the U.S. market due to potential subpotency on December 01, 2020, and December 08, 2020, respectively.\u003Cbr>\nIn response to this letter provide the following:\u003C\u002Fp>\n\n\u003Cp>• A detailed investigation into how the hand sanitizer drug product described above, which was labeled as containing 68% ethanol, in fact contained an average of 42% ethanol.\u003Cbr>\n• A list of all raw materials used to manufacture all of your hand sanitizer drug products, including the suppliers’ names, addresses, and contact information.\u003Cbr>\n• A list of all batches of any hand sanitizer drug products shipped to the United States by your firm, and a full reconciliation of all material you distributed.\u003Cbr>\n• Copies of the complete batch records for all batches distributed to the U.S.\u003Cbr>\n\u003Cbr>\nThe subpotency of hand sanitizer drug products labeled as manufactured in your facility demonstrates that the quality assurance within your facility is not functioning in accordance with CGMP requirements under section 501(a)(2)(B) of the FD&amp;C Act.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drug and Misbranding Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Pristine Hand Sanitizer Gel is a “drug” as defined by section 201(g)(1)(B) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(B), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For under section 201(g)(1)(C) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(C), because it is intended to affect the structure or any function of the body. Specifically, this product is intended for use as a consumer topical antiseptic.\u003C\u002Fp>\n\n\u003Cp>Examples of claims observed on the Pristine Hand Sanitizer Gel product label that provide evidence of the intended use (as defined in 21 CFR 201.128) of the product include, but may not be limited to, the following:\u003C\u002Fp>\n\n\u003Cp>“Hand Sanitizer . . . DRUG FACTS . . . Purpose: Antiseptic . . . Uses: Helps reduce bacteria on skin. . . Wet hands thoroughly with product and allow to dry without wiping.”\u003C\u002Fp>\n\n\u003Cp>This topical antiseptic product is a “new drug” within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), because it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. New drugs may not be introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a), unless they are lawfully marketed under section 505G of the FD&amp;C Act (which is not the case for this product, as further described below). No FDA-approved application pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, is in effect for this product, nor are we aware of any adequate and well-controlled clinical studies in the published literature that support a determination that your Pristine Hand Sanitizer Gel drug product is GRASE for use under the conditions suggested, recommended, or prescribed in its labeling. Accordingly, this product is an unapproved new drug marketed in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C 355(a) and 331(d).\u003C\u002Fp>\n\n\u003Cp>We note that over-the-counter (OTC) topical antiseptic products had been the subject of rulemaking under the Agency’s OTC Drug Review. In particular, such products were addressed in a tentative final monograph (TFM) entitled “Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Tentative Final Monograph for Health-Care Antiseptic Drug Products,” Proposed Rule, 59 FR 31402 (June 17, 1994) (1994 TFM), as further amended by “Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Proposed Amendment of the Tentative Final Monograph; Reopening of Administrative Record,” Proposed Rule, 81 FR 42912 (June 30, 2016)(Consumer Antiseptic Rubs Proposed Rule). Over the course of these rulemakings, three active ingredients (benzalkonium chloride, ethyl alcohol (ethanol), and isopropyl alcohol) were classified as Category III for use in consumer antiseptic rub products, meaning that additional safety and effectiveness data are needed to support a determination that a drug product containing one of these active ingredients would be GRASE for use as a consumer antiseptic rub.\u003C\u002Fp>\n\n\u003Cp>Section 505G of the FD&amp;C Act addresses nonprescription drugs marketed without an approved application. Under 505G(a)(3) of the FD&amp;C Act, drugs that were classified as Category III for safety or effectiveness in a TFM that is the most recently applicable proposal or determination for such drug issued under 21 CFR Part 330 – and that were not classified as Category II for safety or effectiveness – are not required to have an approved application under section 505 in order to be marketed, as long as they are in conformity with the relevant conditions of use outlined in the applicable TFM, including the active ingredient, and comply with all other applicable requirements.\u003C\u002Fp>\n\n\u003Cp>However, Pristine Hand Sanitizer Gel does not conform to the 1994 TFM, as further amended by the 2016 Consumer Antiseptic Rub proposed rule, nor any other TFM, proposed rule, or final rule, and does not meet the conditions under section 505G(a)(3) of the FD&amp;C Act for marketing without an approved application under section 505.\u003C\u002Fp>\n\n\u003Cp>According to the product label, Pristine Hand Sanitizer Gel purportedly contains the active ingredient ethyl alcohol (ethanol) 68% v\u002Fv. However, as previously discussed, FDA laboratory analysis of a batch of this product detained at the border demonstrated that Pristine Hand Sanitizer Gel contains ethanol in a concentration of ethanol that is less than the 68% v\u002Fv declared on the label and less than the amount of ethanol described in the 1994 TFM.\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Such a product does not conform with the TFM and other applicable requirements, nor is it consistent with the formulations described in the guidances setting forth FDA’s temporary policies for hand sanitizers during the COVID-19 public health emergency.\u003Csup>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>Additionally, this hand sanitizer is misbranded under section 502(a) of the FD&amp;C Act, 21 U.S.C. 352(a), because its labeling is false or misleading. As noted above, Pristine Hand Sanitizer Gel is labeled to contain ethanol 68% v\u002Fv. However, FDA laboratory analysis of a sample from a batch of this product demonstrates that the product contains concentrations of ethanol that are far less than that stated on its product label. Thus, the misleading representations of the concentration of the active ingredient ethanol on the Pristine Hand Sanitizer Gel labeling cause this product to be misbranded under section 502(a) of the FD&amp;C Act, 21 U.S.C. 352(a).\u003C\u002Fp>\n\n\u003Cp>Lastly, this product is misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee) because Pristine Hand Sanitizer Gel is a nonprescription drug subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, but does not comply with the requirements for marketing under that section and is not the subject of an application approved under section 505 of the FD&amp;C Act, 21 U.S.C. 355.\u003C\u002Fp>\n\n\u003Cp>The introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements if your firm intends to resume manufacturing drugs for the U.S. market. We also recommend that the qualified consultant perform a comprehensive audit of your entire operation for CGMP compliance and that the consultant evaluates the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations associated with your drug products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>Note that FDA placed all drugs and drug products manufactured by your firm on Import Alert 66-78 on December 22, 2020, as the methods used in and controls used for the manufacture, processing, packing, or holding of these products do not appear to conform to current good manufacturing practices within the meaning of section 501(a)(2)(B) of the FD&amp;C Act. Drugs and drug products that appear to be adulterated or misbranded may be detained or refused admission without physical examination.\u003C\u002Fp>\n\n\u003Cp>All drugs and drug products manufactured by your firm may remain listed on this import alert, until there is evidence establishing that the conditions that gave rise to the appearance of a violation have been resolved, and the Agency has confidence that future entries will be in compliance with the Act. This may include an inspection prior to the agency considering the appearance of adulteration to be addressed.\u003C\u002Fp>\n\n\u003Cp>If you decide you want to manufacture drugs for the United States in the future, request a Regulatory Meeting to discuss corrective actions.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot do so within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov\u003C\u002Fp>\n\n\u003Cp>Please identify your response with FEI 3016808324 and ATTN: Towanda Terrell.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Francis Godwin\u003Cbr>\nDirector\u003Cbr>\nOffice of Manufacturing Quality\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003C\u002Fp>\n\n\u003Cp>CC:\u003Cbr>\nRegistered US Agent:\u003Cbr>\nEport USA LLC\u003Cbr>\nVeronica Ortiz de Montellano\u003Cbr>\n6200 Savoy Dr.\u003Cbr>\nHouston, TX 77036\u003C\u002Fp>\n\n\u003Cp>______________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> \u003Ca href=\"https:\u002F\u002Fwww.cdc.gov\u002Fhandwashing\u002Fhand-sanitizer-use.html\">https:\u002F\u002Fwww.cdc.gov\u002Fhandwashing\u002Fhand-sanitizer-use.html\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Due to an increased demand for alcohol-based hand sanitizers during the COVID-19 pandemic, FDA published the Guidance for Industry: Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19) on March 19, 2020, and subsequently updated the guidance several times, most recently on February 10, 2021. This guidance communicates the Agency’s temporary policy that we do not intend to take action against firms for CGMP violations under section 501(a)(2)(B) of the FD&amp;C Act if such firms prepare alcohol-based hand sanitizers for consumer use (or for use as a health care personnel hand rub) during the public health emergency, provided certain circumstances described in the guidance are present. These circumstances include preparation of hand sanitizer products using only the ingredients and formulas set forth in the guidance. In addition to the violative sample results detailed above that demonstrate the subpotency of hand sanitizer products labeled as manufactured at your facility, a review of the drug products’ labeling further indicates that this product is not prepared consistent with FDA’s temporary policy set forth in the guidance. Therefore, this product does not fall within the Agency’s temporary policy not to take action against firms manufacturing hand sanitizer products for violations of section 501(a)(2)(B) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> The 1994 TFM, which does not distinguish between antiseptic hand washes and rubs, proposed for antiseptic handwashes and healthcare personnel handwashes an alcohol concentration of 60 to 95% by volume in an aqueous solution: 59 FR at 31442. Later amendments to the 1994 TFM distinguished between antiseptic hand washes and rubs, and between consumer and healthcare personnel antiseptics, but did not change the alcohol concentration originally proposed in 1994.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> See, e.g., \u003Cem>Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19)\u003C\u002Fem>. Because Pristine Hand Sanitizer Gel is not consistent with the formulations described in these guidances, it does not fall within any temporary Agency policy not to take action against firms manufacturing hand sanitizer products for violations of section 505 of the FD&amp;C Act.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Luis Armando Garcia Olivares\n\nRecipient Title\n\nCEO\n\nGaza Proveedora De Servicios De Hospedaje Y Alimentacion\n\nCalle Castille 1473-A Colonia Jardines de la Reyna\n\n45410 Tonala, Jal.\n\nMexico\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWarning Letter 320-21-31\n\nMarch 01, 2021\n\nDear Mr. Olivares:\n\nYour firm was recently registered as a human drug manufacturer. The U.S. Food and Drug Administration (FDA) conducted testing of a consumer antiseptic hand rub drug product (also referred to as a consumer hand sanitizer) labeled as Pristine Hand Sanitizer Gel. This drug product was labeled as manufactured at your facility, Gaza Proveedora De Servicios De Hospedaje Y Alimentacion, FEI 3016808324, at Calle Castille 1473-A Colonia Jardines de la Reyna, Tonala, Jalisco, Mexico. Following an attempt to import Pristine Hand Sanitizer Gel into the United States, it was detained and refused admission at the border.\n\nThe results of FDA laboratory testing of a batch of this product detained at the border demonstrate that this drug product labeled as manufactured at your facility is adulterated within the meaning of section 501(c) of the Federal Food, Drug, and Cosmetic Act (FD&C Act or Act), 21 U.S.C. 351(c), in that its strength, purity, or quality falls below that which it purports or is represented to possess. In addition, this product is adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act (21 U.S.C. 351(a)(2)(B)), in that the subpotency demonstrates that the quality assurance within your facility is not functioning in accordance with Current Good Manufacturing Practice (CGMP) requirements.\n\nIn addition, Pristine Hand Sanitizer Gel drug product is an unapproved new drug introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the FD&C Act, 21 U.S.C. 355(a), and is misbranded under sections 502(a) and (ee) of the FD&C Act, 21 U.S.C. 352(a) and (ee). Introduction or delivery for introduction of such a product into interstate commerce is prohibited under sections 301(d) and (a) of the FD&C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\n\nAdulteration Violations\n\nPristine Hand Sanitizer Gel, labeled as manufactured at your facility, is labeled to contain 68% volume\u002Fvolume (v\u002Fv) of the active ingredient alcohol ethyl alcohol (ethanol). However, FDA laboratory testing of a batch of this product detained at the border found that the drug product contained an average of only 42% v\u002Fv ethanol. This hand sanitizer drug product is adulterated under section 501(c) of the FD&C Act in that the active ingredient of ethanol is present at levels in the product lower than that which is declared on its label.\n\nCDC recommends1 that, if soap and water are not readily available, consumers use an alcohol-based hand sanitizer that contains not less than 60% alcohol (ethanol). This is the minimum active ingredient concentration of ethanol specified in the 1994 Tentative Final Monograph for Health-Care Antiseptic Drug Products (59 FR 31402), as further amended by “Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Proposed Amendment of the Tentative Final Monograph; Reopening of Administrative Record,” Proposed Rule, 81 FR 42912 (June 30, 2016).\n\nOn November 20, 2020, FDA held a teleconference with your registered U.S. Agent, Eport USA, LLC, but your firm did not attend. We recommended to your U.S. agent that you consider removing all of your firm’s hand sanitizer drug products currently in distribution to the U.S. market.\n\nOn November 20, 2020 FDA notified the public of the subpotency of your hand sanitizer drug product at the following website: https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-updates-hand-sanitizers-consumers-should-not-use.\n\nYou issued a voluntary nationwide recall of Pristine Hand Sanitizer Gel and Zapien Productos Hand Sanitizer Gel within expiry that was distributed in the U.S. market due to potential subpotency on December 01, 2020, and December 08, 2020, respectively.\n\nIn response to this letter provide the following:\n\n• A detailed investigation into how the hand sanitizer drug product described above, which was labeled as containing 68% ethanol, in fact contained an average of 42% ethanol.\n\n• A list of all raw materials used to manufacture all of your hand sanitizer drug products, including the suppliers’ names, addresses, and contact information.\n\n• A list of all batches of any hand sanitizer drug products shipped to the United States by your firm, and a full reconciliation of all material you distributed.\n\n• Copies of the complete batch records for all batches distributed to the U.S.\n\nThe subpotency of hand sanitizer drug products labeled as manufactured in your facility demonstrates that the quality assurance within your facility is not functioning in accordance with CGMP requirements under section 501(a)(2)(B) of the FD&C Act.2\n\nUnapproved New Drug and Misbranding Violations\n\nPristine Hand Sanitizer Gel is a “drug” as defined by section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For under section 201(g)(1)(C) of the FD&C Act, 21 U.S.C. 321(g)(1)(C), because it is intended to affect the structure or any function of the body. Specifically, this product is intended for use as a consumer topical antiseptic.\n\nExamples of claims observed on the Pristine Hand Sanitizer Gel product label that provide evidence of the intended use (as defined in 21 CFR 201.128) of the product include, but may not be limited to, the following:\n\n“Hand Sanitizer . . . DRUG FACTS . . . Purpose: Antiseptic . . . Uses: Helps reduce bacteria on skin. . . Wet hands thoroughly with product and allow to dry without wiping.”\n\nThis topical antiseptic product is a “new drug” within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), because it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. New drugs may not be introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a), unless they are lawfully marketed under section 505G of the FD&C Act (which is not the case for this product, as further described below). No FDA-approved application pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, is in effect for this product, nor are we aware of any adequate and well-controlled clinical studies in the published literature that support a determination that your Pristine Hand Sanitizer Gel drug product is GRASE for use under the conditions suggested, recommended, or prescribed in its labeling. Accordingly, this product is an unapproved new drug marketed in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C 355(a) and 331(d).\n\nWe note that over-the-counter (OTC) topical antiseptic products had been the subject of rulemaking under the Agency’s OTC Drug Review. In particular, such products were addressed in a tentative final monograph (TFM) entitled “Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Tentative Final Monograph for Health-Care Antiseptic Drug Products,” Proposed Rule, 59 FR 31402 (June 17, 1994) (1994 TFM), as further amended by “Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Proposed Amendment of the Tentative Final Monograph; Reopening of Administrative Record,” Proposed Rule, 81 FR 42912 (June 30, 2016)(Consumer Antiseptic Rubs Proposed Rule). Over the course of these rulemakings, three active ingredients (benzalkonium chloride, ethyl alcohol (ethanol), and isopropyl alcohol) were classified as Category III for use in consumer antiseptic rub products, meaning that additional safety and effectiveness data are needed to support a determination that a drug product containing one of these active ingredients would be GRASE for use as a consumer antiseptic rub.\n\nSection 505G of the FD&C Act addresses nonprescription drugs marketed without an approved application. Under 505G(a)(3) of the FD&C Act, drugs that were classified as Category III for safety or effectiveness in a TFM that is the most recently applicable proposal or determination for such drug issued under 21 CFR Part 330 – and that were not classified as Category II for safety or effectiveness – are not required to have an approved application under section 505 in order to be marketed, as long as they are in conformity with the relevant conditions of use outlined in the applicable TFM, including the active ingredient, and comply with all other applicable requirements.\n\nHowever, Pristine Hand Sanitizer Gel does not conform to the 1994 TFM, as further amended by the 2016 Consumer Antiseptic Rub proposed rule, nor any other TFM, proposed rule, or final rule, and does not meet the conditions under section 505G(a)(3) of the FD&C Act for marketing without an approved application under section 505.\n\nAccording to the product label, Pristine Hand Sanitizer Gel purportedly contains the active ingredient ethyl alcohol (ethanol) 68% v\u002Fv. However, as previously discussed, FDA laboratory analysis of a batch of this product detained at the border demonstrated that Pristine Hand Sanitizer Gel contains ethanol in a concentration of ethanol that is less than the 68% v\u002Fv declared on the label and less than the amount of ethanol described in the 1994 TFM.3 Such a product does not conform with the TFM and other applicable requirements, nor is it consistent with the formulations described in the guidances setting forth FDA’s temporary policies for hand sanitizers during the COVID-19 public health emergency.4\n\nAdditionally, this hand sanitizer is misbranded under section 502(a) of the FD&C Act, 21 U.S.C. 352(a), because its labeling is false or misleading. As noted above, Pristine Hand Sanitizer Gel is labeled to contain ethanol 68% v\u002Fv. However, FDA laboratory analysis of a sample from a batch of this product demonstrates that the product contains concentrations of ethanol that are far less than that stated on its product label. Thus, the misleading representations of the concentration of the active ingredient ethanol on the Pristine Hand Sanitizer Gel labeling cause this product to be misbranded under section 502(a) of the FD&C Act, 21 U.S.C. 352(a).\n\nLastly, this product is misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee) because Pristine Hand Sanitizer Gel is a nonprescription drug subject to section 505G of the FD&C Act, 21 U.S.C. 355h, but does not comply with the requirements for marketing under that section and is not the subject of an application approved under section 505 of the FD&C Act, 21 U.S.C. 355.\n\nThe introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements if your firm intends to resume manufacturing drugs for the U.S. market. We also recommend that the qualified consultant perform a comprehensive audit of your entire operation for CGMP compliance and that the consultant evaluates the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations associated with your drug products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nNote that FDA placed all drugs and drug products manufactured by your firm on Import Alert 66-78 on December 22, 2020, as the methods used in and controls used for the manufacture, processing, packing, or holding of these products do not appear to conform to current good manufacturing practices within the meaning of section 501(a)(2)(B) of the FD&C Act. Drugs and drug products that appear to be adulterated or misbranded may be detained or refused admission without physical examination.\n\nAll drugs and drug products manufactured by your firm may remain listed on this import alert, until there is evidence establishing that the conditions that gave rise to the appearance of a violation have been resolved, and the Agency has confidence that future entries will be in compliance with the Act. This may include an inspection prior to the agency considering the appearance of adulteration to be addressed.\n\nIf you decide you want to manufacture drugs for the United States in the future, request a Regulatory Meeting to discuss corrective actions.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot do so within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov\n\nPlease identify your response with FEI 3016808324 and ATTN: Towanda Terrell.\n\nSincerely,\n\n\u002FS\u002F\n\nFrancis Godwin\n\nDirector\n\nOffice of Manufacturing Quality\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nCC:\n\nRegistered US Agent:\n\nEport USA LLC\n\nVeronica Ortiz de Montellano\n\n6200 Savoy Dr.\n\nHouston, TX 77036\n\n______________________________\n\n1 https:\u002F\u002Fwww.cdc.gov\u002Fhandwashing\u002Fhand-sanitizer-use.html\n\n2 Due to an increased demand for alcohol-based hand sanitizers during the COVID-19 pandemic, FDA published the Guidance for Industry: Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19) on March 19, 2020, and subsequently updated the guidance several times, most recently on February 10, 2021. This guidance communicates the Agency’s temporary policy that we do not intend to take action against firms for CGMP violations under section 501(a)(2)(B) of the FD&C Act if such firms prepare alcohol-based hand sanitizers for consumer use (or for use as a health care personnel hand rub) during the public health emergency, provided certain circumstances described in the guidance are present. These circumstances include preparation of hand sanitizer products using only the ingredients and formulas set forth in the guidance. In addition to the violative sample results detailed above that demonstrate the subpotency of hand sanitizer products labeled as manufactured at your facility, a review of the drug products’ labeling further indicates that this product is not prepared consistent with FDA’s temporary policy set forth in the guidance. Therefore, this product does not fall within the Agency’s temporary policy not to take action against firms manufacturing hand sanitizer products for violations of section 501(a)(2)(B) of the FD&C Act.\n\n3 The 1994 TFM, which does not distinguish between antiseptic hand washes and rubs, proposed for antiseptic handwashes and healthcare personnel handwashes an alcohol concentration of 60 to 95% by volume in an aqueous solution: 59 FR at 31442. Later amendments to the 1994 TFM distinguished between antiseptic hand washes and rubs, and between consumer and healthcare personnel antiseptics, but did not change the alcohol concentration originally proposed in 1994.\n\n4 See, e.g., Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19). Because Pristine Hand Sanitizer Gel is not consistent with the formulations described in these guidances, it does not fall within any temporary Agency policy not to take action against firms manufacturing hand sanitizer products for violations of section 505 of the FD&C Act.","Gaza Proveedora De Servicios De Hospedaje Y Alimentacion","gaza-proveedora-de-servicios-de-hospedaje-y-alimentacion-611881-03012021","2026-08-18T06:42:29.386127+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgaza-proveedora-de-servicios-de-hospedaje-y-alimentacion-611881-03012021","2026-10-26T08:08:44.780499+00:00","2021-03-09","611881","Mr. Luis Armando Garcia Olivares","2026-08-20T03:18:07.551+00:00","VIA UPS","2021-03-01",{"id":118,"raw":119,"subject":62,"body_html":123,"body_text":124,"firm_name":125,"letter_id":126,"created_at":67,"fei_number":20,"letter_url":127,"updated_at":128,"action_type":23,"case_status":48,"posted_date":129,"marcs_cms_no":130,"product_type":27,"closeout_date":20,"issuing_office":39,"recipient_name":131,"body_fetched_at":132,"delivery_method":73,"recipient_title":20,"reference_number":133,"action_taken_date":134,"medical_device_id":20,"response_letter_date":20},179,[120,121,122,39,62,13,13,13],"\u003Ctime datetime=\"2026-05-12T04:00:00Z\">05\u002F12\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-04-29T04:00:00Z\">04\u002F29\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmukesh-b-chandre-md-mbbsashirwad-hospital-research-centre-724911-04292026\">Mukesh B. Chandre, M.D., MBBS\u002FAshirwad Hospital &amp; Research Centre \u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE AND VIA E-MAIL\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>26-HFD-45-04-01\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mukesh B. Chandre, M.D., MBBS\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Mukesh B. Chandre, M.D., MBBS\u002FAshirwad Hospital &amp; Research Centre \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Maratha Section, Near Jijamata Udhyan\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Ulhasnagar\u003C\u002Fspan> \u003Cspan>421004\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Maharashtra\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>India\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA Ref. No.: 26-HFD-45-04-01\u003C\u002Fp>\u003Cp>Dear Dr. Chandre:\u003C\u002Fp>\u003Cp>This Warning Letter informs you of objectionable conditions observed during the U.S. Food and Drug Administration (FDA) inspection conducted at Ashirwad Hospital &amp; Research Centre in Ulhasnagar, Maharashtra, India, between May 5 and May 9, 2025. The investigator representing FDA reviewed your conduct of a clinical in vivo bioequivalence study (Protocol 0270-22, “A Multicenter, Open Label, Balanced, Randomized, Two-Treatment, Two-Period, Two-Sequence, Single Dose, Crossover, Bioequivalence Study between two formulations of Doxorubicin Hydrochloride Liposome Injection 20 mg\u002F10 mL (50 mg\u002Fm\u003Csup>2\u003C\u002Fsup> dose) (Doxorubicin- Test compared with Doxorubicin-Reference) in Patients with Advanced Ovarian Cancer”) of the investigational product doxorubicin hydrochloride liposome injection 20 mg\u002F10 mL, performed for Qilu Pharmaceutical (Hainan) Co., Ltd.\u003C\u002Fp>\u003Cp>This inspection was conducted as a part of FDA’s Bioresearch Monitoring Program, which includes inspections designed to evaluate the conduct of research and to help ensure that the rights, safety, and welfare of human subjects have been protected.\u003C\u002Fp>\u003Cp>At the conclusion of the inspection, the FDA investigator presented and discussed with you the Form FDA 483, Inspectional Observations. We acknowledge receipt of your May 28, 2025, written response to the Form FDA 483.\u003C\u002Fp>\u003Cp>From our review of the FDA Establishment Inspection Report, the documents submitted with that report, and your written response dated May 28, 2025, it appears that you did not adhere to the applicable statutory requirements in the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) and applicable regulations contained in Title 21 of the Code of Federal Regulations, parts 312 (21 CFR 312) and 50 (21 CFR 50) governing the conduct of clinical investigations and the protection of human subjects.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> We wish to emphasize the following:\u003C\u002Fp>\u003Cp>\u003Cstrong>You failed to obtain informed consent in accordance with the provisions of 21 CFR part 50 [21 CFR 312.60 and 21 CFR 50.20].\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>As a clinical investigator, you are required to obtain informed consent in accordance with 21 CFR part 50. FDA’s regulations at 21 CFR 50.20 state that, except as provided in 21 CFR 50.22, 50.23, and 50.24,\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> no investigator may involve a human being as a subject in research covered by the regulations unless the investigator has obtained the legally effective informed consent of the subject or the subject’s legally authorized representative. Under 21 CFR 50.20, “an investigator shall seek…[informed] consent only under circumstances that provide the prospective subject or the representative sufficient opportunity to consider whether or not to participate and that minimize the possibility of coercion or undue influence”.\u003C\u002Fp>\u003Cp>You failed to seek informed consent for the above-referenced clinical investigation under circumstances that provided the prospective subject or the representative sufficient opportunity or information to consider whether or not to participate and that minimized the possibility of undue influence. Specifically, Section 1 of the informed consent form (ICF) stated that all reference to the words “study drug” throughout the ICF can mean Doxorubicin-Test and Doxorubicin-Reference. Section 10 of the ICF stated, “There is evidence that this study drug is effective and indicated in your disease condition.” In addition, Section 4 stated that liposomal doxorubicin is already approved by various regulatory authorities to treat the disease condition. Sections 4 and 10 also did not specify whether “liposomal doxorubicin” or “study drug”, and the statements concerning their approval or effectiveness, respectively, were applicable to the reference product or the test product. The lack of clarity may lead individuals to mistaken conclusions about the investigational product and whether it had already been demonstrated to be effective. Further, statements that overstate the possible benefit of the investigational product may unduly influence individuals to agree to participate when they might not otherwise do so.\u003C\u002Fp>\u003Cp>In your May 28, 2025, written response to the Form FDA 483, you stated that the word “study drug” should have been described as “approved study drug”. You also stated that the Ethics Committee approved the ICF, you complied with all other requirements for the ICF, the ICF adequately described the risk of the test product in other sections, and you, as the clinical investigator, had consent discussions with trial participants that clarified the experimental nature, the associated risk, and that there is no guaranteed benefit of the test drug.\u003C\u002Fp>\u003Cp>In addition, you stated that the CRO revised the global ICF template to improve the description of the study drugs and to improve the section describing the study drug benefits. You also stated that your site has taken the following corrective and preventive actions, including: (1) reviewed consent forms of ongoing studies; (2) notified the ethics committee of the inspectional observations; (3) revised the site’s SOP on the informed consent process to include a provision for the investigator or qualified staff to review the content of the informed consent document for compliance with regulatory requirements; and (4) trained site personnel on the revised SOP and regulatory guidance\u003C\u002Fp>\u003Cp>While we acknowledge the corrective and preventive actions that your site has taken, your written response is inadequate because you did not provide sufficient details about how you, as the clinical investigator, will ensure adequate compliance with the informed consent regulations at 21 CFR part 50. Without this information, we are unable to determine whether your corrective actions appear adequate to prevent similar violations in future clinical investigations.\u003C\u002Fp>\u003Cp>We emphasize that as the clinical investigator, you are ultimately responsible for compliance with all applicable FDA regulations governing the conduct of clinical investigations and the protection of human subjects, including obtaining legal effective informed consent from subjects before their enrollment. Your failure to obtain informed consent in accordance with 21 CFR part 50 before involving subjects in research jeopardizes the rights, safety, and welfare of subjects and raises concerns about whether subjects had an adequate opportunity to fully assess the risks and benefits of their participation in the clinical investigation.\u003C\u002Fp>\u003Cp>This letter is not intended to be an all-inclusive list of deficiencies with your clinical study of an investigational product. It is your responsibility to ensure adherence to each requirement of the law and relevant FDA regulations. You should address any deficiencies and establish procedures to ensure that any ongoing or future studies comply with FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you with an opportunity to address the deficiencies noted above. Within 15 business days of your receipt of this letter, you should notify this office in writing of the actions you have taken to prevent similar violations in the future. Failure to address this matter adequately may lead to regulatory action without further notice to you. If you believe that you have complied with the FD&amp;C Act and relevant regulations, please include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Your written response, and any questions or concerns about this letter or the inspection, should be sent via email to the FDA at CDER-OSI-Communications@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely yours,\u003Cbr>{See appended electronic signature page}\u003Cbr>David C. Burrow, Pharm.D., J.D.\u003Cbr>Director\u003Cbr>Office of Scientific Investigations\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>David Burrow Digitally signed by David Burrow\u003Cbr>Date: 4\u002F29\u002F2026 12:30:34 PM EDT\u003C\u002Fp>\u003Cp>______________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> In accordance with 21 CFR 320.31(c), the provisions of 21 CFR parts 312 and 50 are applicable to this bioequivalence study in humans because Protocol 0270-22 was conducted under an Investigational New Drug application (IND).\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> The exceptions provided in 21 CFR 50.22, 50.23, and 50.24 are not applicable here.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE AND VIA E-MAIL\n\nReference #:\n\n26-HFD-45-04-01\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMukesh B. Chandre, M.D., MBBS\n\nMukesh B. Chandre, M.D., MBBS\u002FAshirwad Hospital & Research Centre\n\nMaratha Section, Near Jijamata Udhyan\n\nUlhasnagar 421004\n\nMaharashtra\n\nIndia\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\nFDA Ref. No.: 26-HFD-45-04-01\nDear Dr. Chandre:\nThis Warning Letter informs you of objectionable conditions observed during the U.S. Food and Drug Administration (FDA) inspection conducted at Ashirwad Hospital & Research Centre in Ulhasnagar, Maharashtra, India, between May 5 and May 9, 2025. The investigator representing FDA reviewed your conduct of a clinical in vivo bioequivalence study (Protocol 0270-22, “A Multicenter, Open Label, Balanced, Randomized, Two-Treatment, Two-Period, Two-Sequence, Single Dose, Crossover, Bioequivalence Study between two formulations of Doxorubicin Hydrochloride Liposome Injection 20 mg\u002F10 mL (50 mg\u002Fm2 dose) (Doxorubicin- Test compared with Doxorubicin-Reference) in Patients with Advanced Ovarian Cancer”) of the investigational product doxorubicin hydrochloride liposome injection 20 mg\u002F10 mL, performed for Qilu Pharmaceutical (Hainan) Co., Ltd.\nThis inspection was conducted as a part of FDA’s Bioresearch Monitoring Program, which includes inspections designed to evaluate the conduct of research and to help ensure that the rights, safety, and welfare of human subjects have been protected.\nAt the conclusion of the inspection, the FDA investigator presented and discussed with you the Form FDA 483, Inspectional Observations. We acknowledge receipt of your May 28, 2025, written response to the Form FDA 483.\nFrom our review of the FDA Establishment Inspection Report, the documents submitted with that report, and your written response dated May 28, 2025, it appears that you did not adhere to the applicable statutory requirements in the Federal Food, Drug, and Cosmetic Act (FD&C Act) and applicable regulations contained in Title 21 of the Code of Federal Regulations, parts 312 (21 CFR 312) and 50 (21 CFR 50) governing the conduct of clinical investigations and the protection of human subjects.1 We wish to emphasize the following:\nYou failed to obtain informed consent in accordance with the provisions of 21 CFR part 50 [21 CFR 312.60 and 21 CFR 50.20].\nAs a clinical investigator, you are required to obtain informed consent in accordance with 21 CFR part 50. FDA’s regulations at 21 CFR 50.20 state that, except as provided in 21 CFR 50.22, 50.23, and 50.24,2 no investigator may involve a human being as a subject in research covered by the regulations unless the investigator has obtained the legally effective informed consent of the subject or the subject’s legally authorized representative. Under 21 CFR 50.20, “an investigator shall seek…[informed] consent only under circumstances that provide the prospective subject or the representative sufficient opportunity to consider whether or not to participate and that minimize the possibility of coercion or undue influence”.\nYou failed to seek informed consent for the above-referenced clinical investigation under circumstances that provided the prospective subject or the representative sufficient opportunity or information to consider whether or not to participate and that minimized the possibility of undue influence. Specifically, Section 1 of the informed consent form (ICF) stated that all reference to the words “study drug” throughout the ICF can mean Doxorubicin-Test and Doxorubicin-Reference. Section 10 of the ICF stated, “There is evidence that this study drug is effective and indicated in your disease condition.” In addition, Section 4 stated that liposomal doxorubicin is already approved by various regulatory authorities to treat the disease condition. Sections 4 and 10 also did not specify whether “liposomal doxorubicin” or “study drug”, and the statements concerning their approval or effectiveness, respectively, were applicable to the reference product or the test product. The lack of clarity may lead individuals to mistaken conclusions about the investigational product and whether it had already been demonstrated to be effective. Further, statements that overstate the possible benefit of the investigational product may unduly influence individuals to agree to participate when they might not otherwise do so.\nIn your May 28, 2025, written response to the Form FDA 483, you stated that the word “study drug” should have been described as “approved study drug”. You also stated that the Ethics Committee approved the ICF, you complied with all other requirements for the ICF, the ICF adequately described the risk of the test product in other sections, and you, as the clinical investigator, had consent discussions with trial participants that clarified the experimental nature, the associated risk, and that there is no guaranteed benefit of the test drug.\nIn addition, you stated that the CRO revised the global ICF template to improve the description of the study drugs and to improve the section describing the study drug benefits. You also stated that your site has taken the following corrective and preventive actions, including: (1) reviewed consent forms of ongoing studies; (2) notified the ethics committee of the inspectional observations; (3) revised the site’s SOP on the informed consent process to include a provision for the investigator or qualified staff to review the content of the informed consent document for compliance with regulatory requirements; and (4) trained site personnel on the revised SOP and regulatory guidance\nWhile we acknowledge the corrective and preventive actions that your site has taken, your written response is inadequate because you did not provide sufficient details about how you, as the clinical investigator, will ensure adequate compliance with the informed consent regulations at 21 CFR part 50. Without this information, we are unable to determine whether your corrective actions appear adequate to prevent similar violations in future clinical investigations.\nWe emphasize that as the clinical investigator, you are ultimately responsible for compliance with all applicable FDA regulations governing the conduct of clinical investigations and the protection of human subjects, including obtaining legal effective informed consent from subjects before their enrollment. Your failure to obtain informed consent in accordance with 21 CFR part 50 before involving subjects in research jeopardizes the rights, safety, and welfare of subjects and raises concerns about whether subjects had an adequate opportunity to fully assess the risks and benefits of their participation in the clinical investigation.\nThis letter is not intended to be an all-inclusive list of deficiencies with your clinical study of an investigational product. It is your responsibility to ensure adherence to each requirement of the law and relevant FDA regulations. You should address any deficiencies and establish procedures to ensure that any ongoing or future studies comply with FDA regulations.\nThis letter notifies you of our findings and provides you with an opportunity to address the deficiencies noted above. Within 15 business days of your receipt of this letter, you should notify this office in writing of the actions you have taken to prevent similar violations in the future. Failure to address this matter adequately may lead to regulatory action without further notice to you. If you believe that you have complied with the FD&C Act and relevant regulations, please include your reasoning and any supporting information for our consideration.\nYour written response, and any questions or concerns about this letter or the inspection, should be sent via email to the FDA at CDER-OSI-Communications@fda.hhs.gov.\nSincerely yours,\n{See appended electronic signature page}\nDavid C. Burrow, Pharm.D., J.D.\nDirector\nOffice of Scientific Investigations\nOffice of Compliance\nCenter for Drug Evaluation and Research\nDavid Burrow Digitally signed by David Burrow\nDate: 4\u002F29\u002F2026 12:30:34 PM EDT\n______________________\n1 In accordance with 21 CFR 320.31(c), the provisions of 21 CFR parts 312 and 50 are applicable to this bioequivalence study in humans because Protocol 0270-22 was conducted under an Investigational New Drug application (IND).\n2 The exceptions provided in 21 CFR 50.22, 50.23, and 50.24 are not applicable here.","Mukesh B. Chandre, M.D., MBBS\u002FAshirwad Hospital & Research Centre","mukesh-b-chandre-md-mbbsashirwad-hospital-research-centre-724911-04292026","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmukesh-b-chandre-md-mbbsashirwad-hospital-research-centre-724911-04292026","2026-10-26T08:09:28.594998+00:00","2026-05-12","724911","Mukesh B. Chandre, M.D., MBBS","2026-08-19T04:42:53.526+00:00","26-HFD-45-04-01","2026-04-29",{"id":136,"raw":137,"subject":144,"body_html":145,"body_text":146,"firm_name":147,"letter_id":148,"created_at":149,"fei_number":20,"letter_url":150,"updated_at":151,"action_type":23,"case_status":24,"posted_date":152,"marcs_cms_no":153,"product_type":27,"closeout_date":154,"issuing_office":141,"recipient_name":155,"body_fetched_at":156,"delivery_method":157,"recipient_title":20,"reference_number":20,"action_taken_date":158,"medical_device_id":20,"response_letter_date":20},3552,[138,139,140,141,142,13,143,13],"\u003Ctime datetime=\"2021-02-09T14:20:00Z\">02\u002F09\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-02-01T05:00:00Z\">02\u002F01\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fhawaii-health-systems-corporation-dba-kona-community-hospital-pharmacy-611130-02012021\">Hawaii Health Systems Corporation dba Kona Community Hospital Pharmacy\u003C\u002Fa>","Division of Pharmaceutical Quality Operations IV","Compounding Pharmacy\u002FAdulterated Drug Products \u003Cbr \u002F>\r\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fhawaii-health-systems-corporation-dba-kona-community-hospital-pharmacy-611130-06272022\">\u003Ctime datetime=\"2022-07-14T04:00:00Z\">07\u002F14\u002F2022\u003C\u002Ftime>\n\u003C\u002Fa>","Compounding Pharmacy\u002FAdulterated Drug Products","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Emily A. Krug\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Director of Pharmacy\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Hawaii Health Systems Corporation dba Kona Community Hospital Pharmacy\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>79-1019 Haukapila Street\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Kealakekua\u003C\u002Fspan>, \u003Cspan>HI\u003C\u002Fspan> \u003Cspan>96750\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:emkrug@hhsc.org\"> emkrug@hhsc.org\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Pharmaceutical Quality Operations IV\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>February 1, 2021\u003C\u002Fp>\n\n\u003Cp>Dear Ms. Krug:\u003C\u002Fp>\n\n\u003Cp>From December 2, 2019, to December 13, 2019, U.S. Food and Drug Administration (FDA) investigators inspected your facility, Hawaii Health Systems Corporation dba Kona Community Hospital Pharmacy, located at 79-1019 Haukapila Street Kealakekua, HI 96750. During the inspection, the investigators noted serious deficiencies in your practices for producing sterile drug products, which put patients at risk.\u003C\u002Fp>\n\n\u003Cp>FDA issued a Form FDA 483 to your firm on December 13, 2019. FDA acknowledges receipt of your facility’s response, dated January 3, 2020, and subsequent correspondence. Based on this inspection, it appears that you produced drug products that violate the Federal Food, Drug, and Cosmetic Act (FDCA).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>A. Compounded Drug Products Under the FDCA\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Section 503A of the FDCA describes the conditions under which human drug products compounded by a licensed pharmacist in a State licensed pharmacy or a Federal facility, or a licensed physician, qualify for exemptions from three sections of the FDCA: compliance with current good manufacturing practice (CGMP) (section 501(a)(2)(B)); labeling with adequate directions for use (section 502(f)(1)); and FDA approval prior to marketing (section 505) [21 U.S.C. §§ 351(a)(2)(B), 352(f)(1) and 355(a)].\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Receipt of valid prescriptions for individually-identified patients is one of the conditions for the exemptions under section 503A.\u003C\u002Fp>\n\n\u003Cp>Specific violations are described below.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>B. Violations of the FDCA\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Adulterated Drug Products\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The FDA investigators noted that drug products intended or expected to be sterile were prepared, packed, or held under insanitary conditions, whereby they may have become contaminated with filth or rendered injurious to health, causing your drug products to be adulterated under section 501(a)(2)(A) of the FDCA. For example, the investigators observed that:\u003C\u002Fp>\n\n\u003Cp>1. You failed to remediate the repeated recovery of microbial contamination from the ISO 7 cleanrooms, ISO 5 biological safety cabinet (BSC), and ISO 5 laminar air flow (LAF) hood where drug products intended to be sterile were prepared. Furthermore, you failed to evaluate whether the identified microbial contamination had any impact on aseptically processed drug products that were prepared in your cleanrooms.\u003C\u002Fp>\n\n\u003Cp>2. Your facility design was deficient because:\u003Cbr>\n(i) the cleanrooms did not have \u003Cstrong>(b)(4)\u003C\u002Fstrong>;\u003Cbr>\n(ii) the cleanrooms were provided with HEPA filtered air \u003Cstrong>(b)(4)\u003C\u002Fstrong>. This HEPA filter was not clamped down in the filter housing, had failed leak testing in 2018, and was not tested for leaks during the cleanroom certification performed in June 2019;\u003Cbr>\n(iii) the air returns in the cleanrooms were located in the ceilings in proximity to the air supply vents;\u003Cbr>\n(iv) \u003Cstrong>(b)(4)\u003C\u002Fstrong> between the ISO 7 hazardous buffer room and the unclassified area were \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> were observed opened at the same time;\u003Cbr>\n(v) a differential pressure cascade could not be maintained between rooms of higher air quality and rooms of lower air quality when the doors to the cleanrooms were closed;\u003Cbr>\n(vi) the air supply vents in the ISO 7 non-hazardous drug room and anteroom had accumulated what appeared to be dust.\u003C\u002Fp>\n\n\u003Cp>3. Your firm failed to perform adequate smoke studies under dynamic conditions to demonstrate unidirectional airflow within the ISO 5 BSC. Therefore, your products intended to be sterile were produced in an environment that may not provide adequate protection against the risk of contamination.\u003C\u002Fp>\n\n\u003Cp>4. Your firm used a non-sterile disinfectant within the ISO 5 aseptic processing area.\u003Cbr>\n\u003Cbr>\nIt is a prohibited act under section 301(k) of the FDCA [21 U.S.C. § 331(k)] to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being adulterated.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>C. Corrective Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>We have reviewed your firm’s response to the Form FDA 483 and subsequent correspondence. We acknowledge that as part of your corrective actions, all drug products intended to be sterile will continue to be assigned a beyond use date (BUD) of 12 hours.\u003C\u002Fp>\n\n\u003Cp>However, regarding your responses related to the insanitary conditions, we cannot fully evaluate the adequacy of the following corrective actions described in your response because you did not include sufficient information or supporting documentation:\u003C\u002Fp>\n\n\u003Cp>1. Your response stated that \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;was intended to be completed by \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You have not provided details describing the finalized design changes or evidence to demonstrate that the design phase has been completed or that the \u003Cstrong>(b)(4)\u003C\u002Fstrong> activities have been planned or performed.\u003C\u002Fp>\n\n\u003Cp>2. You stated that \u003Cstrong>(b)(4)\u003C\u002Fstrong> would be purchased for use while the \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You have not provided evidence to show that this corrective action has been implemented.\u003C\u002Fp>\n\n\u003Cp>3. Your response stated that cleaning the interior of the ISO 5 areas will be performed using sterile \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, you did not provide supporting evidence to demonstrate that sterile \u003Cstrong>(b)(4)\u003C\u002Fstrong> was purchased or whether any modifications or changes have been made to your cleaning practices.\u003C\u002Fp>\n\n\u003Cp>4. You did not provide additional environmental monitoring data to demonstrate that the ISO 5 BSC, ISO 5 LAF, and the cleanrooms are maintained in a state of control.\u003C\u002Fp>\n\n\u003Cp>5. You failed to evaluate whether the recovery of spore-forming organisms indicated a need for more frequent application of a sporicidal agent as part of your routine disinfection program.\u003C\u002Fp>\n\n\u003Cp>Please be aware that section 501(a)(2)(A) of the FDCA concerning insanitary conditions applies regardless of whether drug products you compound meet the conditions of section 503A.\u003C\u002Fp>\n\n\u003Cp>FDA strongly recommends that your management undertake a comprehensive assessment of operations, including facility design, procedures, personnel, processes, maintenance, materials, and systems. In particular, this review should assess your aseptic processing operations. A third-party consultant with relevant sterile drug manufacturing expertise should assist you in conducting this comprehensive evaluation.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>D. Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive statement of violations at your facility. You are responsible for investigating and determining the causes of the violations identified above and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>You should take prompt action to correct the violations cited in this letter. Failure to promptly correct these violations may result in legal action without further notice, including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Within fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps that you have taken to correct violations. Please include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you do not believe that the products discussed above are in violation of the FDCA, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen (15) working days, state the reason for the delay and the time within which you will complete the correction.\u003C\u002Fp>\n\n\u003Cp>Send your written responses to:\u003C\u002Fp>\n\n\u003Cp>CDR Steven E. Porter, Jr.\u003Cbr>\nDirector, Division of Pharmaceutical Quality Operations IV\u003Cbr>\n19701 Fairchild Road\u003Cbr>\nIrvine, CA 92612\u003C\u002Fp>\n\n\u003Cp>Please identify your response with unique identifier 611130. Electronic responses may also be submitted to ORAPHARM4_Responses@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>If you have questions regarding any issues in this letter, please contact Mariza Jafary, Compliance Officer, at \u003Cspan>(949) 608-2977\u003Ca>\u003C\u002Fa>\u003C\u002Fspan>, or Mariza.Jafary@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>CDR Steven E. Porter, Jr.\u003Cbr>\nDirector, Division of Pharmaceutical Quality Operations IV\u003C\u002Fp>\n\n\u003Cp>__________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> We remind you that there are conditions other than those discussed in this letter that must be satisfied to qualify for the exemptions in section 503A of the FDCA.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nEmily A. Krug\n\nRecipient Title\n\nDirector of Pharmacy\n\nHawaii Health Systems Corporation dba Kona Community Hospital Pharmacy\n\n79-1019 Haukapila Street\n\nKealakekua, HI 96750\n\nUnited States\n\nemkrug@hhsc.org\n\nIssuing Office:\n\nDivision of Pharmaceutical Quality Operations IV\n\nUnited States\n\nWARNING LETTER\n\nFebruary 1, 2021\n\nDear Ms. Krug:\n\nFrom December 2, 2019, to December 13, 2019, U.S. Food and Drug Administration (FDA) investigators inspected your facility, Hawaii Health Systems Corporation dba Kona Community Hospital Pharmacy, located at 79-1019 Haukapila Street Kealakekua, HI 96750. During the inspection, the investigators noted serious deficiencies in your practices for producing sterile drug products, which put patients at risk.\n\nFDA issued a Form FDA 483 to your firm on December 13, 2019. FDA acknowledges receipt of your facility’s response, dated January 3, 2020, and subsequent correspondence. Based on this inspection, it appears that you produced drug products that violate the Federal Food, Drug, and Cosmetic Act (FDCA).\n\nA. Compounded Drug Products Under the FDCA\n\nSection 503A of the FDCA describes the conditions under which human drug products compounded by a licensed pharmacist in a State licensed pharmacy or a Federal facility, or a licensed physician, qualify for exemptions from three sections of the FDCA: compliance with current good manufacturing practice (CGMP) (section 501(a)(2)(B)); labeling with adequate directions for use (section 502(f)(1)); and FDA approval prior to marketing (section 505) [21 U.S.C. §§ 351(a)(2)(B), 352(f)(1) and 355(a)].1 Receipt of valid prescriptions for individually-identified patients is one of the conditions for the exemptions under section 503A.\n\nSpecific violations are described below.\n\nB. Violations of the FDCA\n\nAdulterated Drug Products\n\nThe FDA investigators noted that drug products intended or expected to be sterile were prepared, packed, or held under insanitary conditions, whereby they may have become contaminated with filth or rendered injurious to health, causing your drug products to be adulterated under section 501(a)(2)(A) of the FDCA. For example, the investigators observed that:\n\n1. You failed to remediate the repeated recovery of microbial contamination from the ISO 7 cleanrooms, ISO 5 biological safety cabinet (BSC), and ISO 5 laminar air flow (LAF) hood where drug products intended to be sterile were prepared. Furthermore, you failed to evaluate whether the identified microbial contamination had any impact on aseptically processed drug products that were prepared in your cleanrooms.\n\n2. Your facility design was deficient because:\n\n(i) the cleanrooms did not have (b)(4);\n\n(ii) the cleanrooms were provided with HEPA filtered air (b)(4). This HEPA filter was not clamped down in the filter housing, had failed leak testing in 2018, and was not tested for leaks during the cleanroom certification performed in June 2019;\n\n(iii) the air returns in the cleanrooms were located in the ceilings in proximity to the air supply vents;\n\n(iv) (b)(4) between the ISO 7 hazardous buffer room and the unclassified area were (b)(4) and (b)(4) were observed opened at the same time;\n\n(v) a differential pressure cascade could not be maintained between rooms of higher air quality and rooms of lower air quality when the doors to the cleanrooms were closed;\n\n(vi) the air supply vents in the ISO 7 non-hazardous drug room and anteroom had accumulated what appeared to be dust.\n\n3. Your firm failed to perform adequate smoke studies under dynamic conditions to demonstrate unidirectional airflow within the ISO 5 BSC. Therefore, your products intended to be sterile were produced in an environment that may not provide adequate protection against the risk of contamination.\n\n4. Your firm used a non-sterile disinfectant within the ISO 5 aseptic processing area.\n\nIt is a prohibited act under section 301(k) of the FDCA [21 U.S.C. § 331(k)] to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being adulterated.\n\nC. Corrective Actions\n\nWe have reviewed your firm’s response to the Form FDA 483 and subsequent correspondence. We acknowledge that as part of your corrective actions, all drug products intended to be sterile will continue to be assigned a beyond use date (BUD) of 12 hours.\n\nHowever, regarding your responses related to the insanitary conditions, we cannot fully evaluate the adequacy of the following corrective actions described in your response because you did not include sufficient information or supporting documentation:\n\n1. Your response stated that (b)(4) was intended to be completed by (b)(4). You have not provided details describing the finalized design changes or evidence to demonstrate that the design phase has been completed or that the (b)(4) activities have been planned or performed.\n\n2. You stated that (b)(4) would be purchased for use while the (b)(4). You have not provided evidence to show that this corrective action has been implemented.\n\n3. Your response stated that cleaning the interior of the ISO 5 areas will be performed using sterile (b)(4). However, you did not provide supporting evidence to demonstrate that sterile (b)(4) was purchased or whether any modifications or changes have been made to your cleaning practices.\n\n4. You did not provide additional environmental monitoring data to demonstrate that the ISO 5 BSC, ISO 5 LAF, and the cleanrooms are maintained in a state of control.\n\n5. You failed to evaluate whether the recovery of spore-forming organisms indicated a need for more frequent application of a sporicidal agent as part of your routine disinfection program.\n\nPlease be aware that section 501(a)(2)(A) of the FDCA concerning insanitary conditions applies regardless of whether drug products you compound meet the conditions of section 503A.\n\nFDA strongly recommends that your management undertake a comprehensive assessment of operations, including facility design, procedures, personnel, processes, maintenance, materials, and systems. In particular, this review should assess your aseptic processing operations. A third-party consultant with relevant sterile drug manufacturing expertise should assist you in conducting this comprehensive evaluation.\n\nD. Conclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive statement of violations at your facility. You are responsible for investigating and determining the causes of the violations identified above and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nYou should take prompt action to correct the violations cited in this letter. Failure to promptly correct these violations may result in legal action without further notice, including, without limitation, seizure and injunction.\n\nWithin fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps that you have taken to correct violations. Please include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you do not believe that the products discussed above are in violation of the FDCA, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen (15) working days, state the reason for the delay and the time within which you will complete the correction.\n\nSend your written responses to:\n\nCDR Steven E. Porter, Jr.\n\nDirector, Division of Pharmaceutical Quality Operations IV\n\n19701 Fairchild Road\n\nIrvine, CA 92612\n\nPlease identify your response with unique identifier 611130. Electronic responses may also be submitted to ORAPHARM4_Responses@fda.hhs.gov.\n\nIf you have questions regarding any issues in this letter, please contact Mariza Jafary, Compliance Officer, at (949) 608-2977, or Mariza.Jafary@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nCDR Steven E. Porter, Jr.\n\nDirector, Division of Pharmaceutical Quality Operations IV\n\n__________________________\n\n1 We remind you that there are conditions other than those discussed in this letter that must be satisfied to qualify for the exemptions in section 503A of the FDCA.","Hawaii Health Systems Corporation dba Kona Community Hospital Pharmacy","hawaii-health-systems-corporation-dba-kona-community-hospital-pharmacy-611130-02012021","2026-08-18T06:42:29.460824+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fhawaii-health-systems-corporation-dba-kona-community-hospital-pharmacy-611130-02012021","2026-10-26T08:08:53.28171+00:00","2021-02-09","611130","2022-07-14","Emily A. Krug","2026-08-20T03:24:27.426+00:00","Via Email","2021-02-01",7,{"510k":161,"classification":162,"enforcement":163,"event":164,"event_backfill":165,"pma":166,"warning_letter":167},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]